DE122007000024I2 - Verfahren zur herstellung von gasgefüllten lipid-mikropartikeln und gasgefüllte lipid-mikropartikel - Google Patents

Verfahren zur herstellung von gasgefüllten lipid-mikropartikeln und gasgefüllte lipid-mikropartikel

Info

Publication number
DE122007000024I2
DE122007000024I2 DE122007000024C DE122007000024C DE122007000024I2 DE 122007000024 I2 DE122007000024 I2 DE 122007000024I2 DE 122007000024 C DE122007000024 C DE 122007000024C DE 122007000024 C DE122007000024 C DE 122007000024C DE 122007000024 I2 DE122007000024 I2 DE 122007000024I2
Authority
DE
Germany
Prior art keywords
gas
lipid microparticles
filled lipid
filled
microparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE122007000024C
Other languages
English (en)
Other versions
DE122007000024I1 (de
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lantheus Medical Imaging Inc
Original Assignee
Bristol Myers Squibb Medical Imaging Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27491252&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE122007000024(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/076,239 external-priority patent/US5469854A/en
Priority claimed from US08/160,232 external-priority patent/US5542935A/en
Application filed by Bristol Myers Squibb Medical Imaging Inc filed Critical Bristol Myers Squibb Medical Imaging Inc
Publication of DE122007000024I1 publication Critical patent/DE122007000024I1/de
Publication of DE122007000024I2 publication Critical patent/DE122007000024I2/de
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/227—Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1815—Suspensions, emulsions, colloids, dispersions compo-inhalant, e.g. breath tests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/3145—Filters incorporated in syringes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/812—Liposome comprising an antibody, antibody fragment, antigen, or other specific or nonspecific immunoeffector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/927—Diagnostic contrast agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/927—Diagnostic contrast agent
    • Y10S977/929—Ultrasound contrast agent
DE122007000024C 1993-06-11 1994-05-20 Verfahren zur herstellung von gasgefüllten lipid-mikropartikeln und gasgefüllte lipid-mikropartikel Active DE122007000024I2 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US08/076,239 US5469854A (en) 1989-12-22 1993-06-11 Methods of preparing gas-filled liposomes
US15967493A 1993-11-30 1993-11-30
US08/159,687 US5585112A (en) 1989-12-22 1993-11-30 Method of preparing gas and gaseous precursor-filled microspheres
US08/160,232 US5542935A (en) 1989-12-22 1993-11-30 Therapeutic delivery systems related applications
PCT/US1994/005792 WO1994028780A2 (en) 1993-06-11 1994-05-20 Methods of preparing gas and gaseous precursor-filled microspheres
DE69432219T DE69432219T2 (de) 1993-06-11 1994-05-20 Verfahren zur herstellung von gasgefüllten lipid-mikropartikeln und gasgefüllte lipid-mikropartikel

Publications (2)

Publication Number Publication Date
DE122007000024I1 DE122007000024I1 (de) 2007-10-04
DE122007000024I2 true DE122007000024I2 (de) 2011-06-16

Family

ID=27491252

Family Applications (2)

Application Number Title Priority Date Filing Date
DE122007000024C Active DE122007000024I2 (de) 1993-06-11 1994-05-20 Verfahren zur herstellung von gasgefüllten lipid-mikropartikeln und gasgefüllte lipid-mikropartikel
DE69432219T Expired - Lifetime DE69432219T2 (de) 1993-06-11 1994-05-20 Verfahren zur herstellung von gasgefüllten lipid-mikropartikeln und gasgefüllte lipid-mikropartikel

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69432219T Expired - Lifetime DE69432219T2 (de) 1993-06-11 1994-05-20 Verfahren zur herstellung von gasgefüllten lipid-mikropartikeln und gasgefüllte lipid-mikropartikel

Country Status (14)

Country Link
US (4) US5585112A (de)
EP (2) EP1252885A3 (de)
JP (2) JP4274387B2 (de)
CN (1) CN1125654C (de)
AT (1) ATE233574T1 (de)
AU (1) AU683900B2 (de)
CA (1) CA2164845C (de)
DE (2) DE122007000024I2 (de)
DK (1) DK0712293T3 (de)
ES (1) ES2193161T3 (de)
LU (1) LU91325I2 (de)
NL (1) NL300267I2 (de)
PT (1) PT712293E (de)
WO (1) WO1994028780A2 (de)

Families Citing this family (566)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US6088613A (en) 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5305757A (en) 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US6001335A (en) 1989-12-22 1999-12-14 Imarx Pharmaceutical Corp. Contrasting agents for ultrasonic imaging and methods for preparing the same
US5773024A (en) * 1989-12-22 1998-06-30 Imarx Pharmaceutical Corp. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5922304A (en) 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US6146657A (en) 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5656211A (en) * 1989-12-22 1997-08-12 Imarx Pharmaceutical Corp. Apparatus and method for making gas-filled vesicles of optimal size
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5776429A (en) 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
US20010024638A1 (en) * 1992-11-02 2001-09-27 Michel Schneider Stable microbubble suspensions as enhancement agents for ultrasound echography and dry formulations thereof
US6989141B2 (en) * 1990-05-18 2006-01-24 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
EP0504881B2 (de) * 1991-03-22 2000-11-08 Katsuro Tachibana Verstärker zur Ultraschalltherapie von Erkrankungen sowie diesen enthaltende flüssige Arzneimittelzusammensetzungen
GB9106673D0 (en) * 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5874062A (en) 1991-04-05 1999-02-23 Imarx Pharmaceutical Corp. Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
MX9205298A (es) * 1991-09-17 1993-05-01 Steven Carl Quay Medios gaseosos de contraste de ultrasonido y metodo para seleccionar gases para usarse como medios de contraste de ultrasonido
IL108416A (en) 1993-01-25 1998-10-30 Sonus Pharma Inc Colloids with phase difference as contrast ultrasound agents
WO1994016739A1 (en) * 1993-01-25 1994-08-04 Sonus Pharmaceuticals, Inc. Phase shift colloids as ultrasound contrast agents
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
DK0711179T3 (da) 1993-07-30 2005-02-14 Imcor Pharmaceutical Co Stabiliserede sammensætninger med mikrobobler til ultralyd
US5798091A (en) 1993-07-30 1998-08-25 Alliance Pharmaceutical Corp. Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
US6217849B1 (en) * 1993-09-29 2001-04-17 Bracco Research S.A. Liposome suspensions as blood pool imaging contrast agents
US7083572B2 (en) * 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
KR100295173B1 (ko) * 1993-12-15 2001-09-17 엔. 토모브 초음파콘트라스트매질로서유용한가스혼합물
US5736121A (en) 1994-05-23 1998-04-07 Imarx Pharmaceutical Corp. Stabilized homogenous suspensions as computed tomography contrast agents
US5792612A (en) * 1994-06-22 1998-08-11 Helsinki University Licensing, Ltd. Use of lipids to improve the polymerse chain reaction
US5730955A (en) * 1994-08-02 1998-03-24 Molecular Biosystems, Inc. Process for making gas-filled microspheres containing a liquid hydrophobic barrier
US5540909A (en) * 1994-09-28 1996-07-30 Alliance Pharmaceutical Corp. Harmonic ultrasound imaging with microbubbles
US6743779B1 (en) * 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US6383814B1 (en) * 1994-12-09 2002-05-07 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
USRE38971E1 (en) 1995-01-31 2006-02-07 Kabushiki Kaisha Toshiba Ultrasound diagnostic apparatus and method
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US5902604A (en) * 1995-06-06 1999-05-11 Board Of Regents, The University Of Texas System Submicron liposome suspensions obtained from preliposome lyophilizates
US5997898A (en) 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US6139819A (en) 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US5804162A (en) * 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US5897851A (en) * 1995-06-07 1999-04-27 Sonus Pharmaceuticals, Inc. Nucleation and activation of a liquid-in-liquid emulsion for use in ultrasound imaging
US6033645A (en) 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
US6231834B1 (en) 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
GB9511488D0 (en) * 1995-06-07 1995-08-02 Nycomed Imaging As Improvements in or relating to contrast agents
US5780010A (en) * 1995-06-08 1998-07-14 Barnes-Jewish Hospital Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system
US6821506B2 (en) 1995-06-08 2004-11-23 Barnes-Jewish Hospital Site specific binding system, imaging compositions and methods
DE19543077C2 (de) * 1995-11-13 1997-10-16 Schering Ag Verwendung von gashaltigen Metallkomplexen als Ultraschallkontrastmittel
US5840276A (en) * 1996-01-11 1998-11-24 Apfel Enterprises, Inc. Activatable infusable dispersions containing drops of a superheated liquid for methods of therapy and diagnosis
EP0881915B1 (de) * 1996-02-19 2003-04-23 Amersham Health AS Verbesserungen an (oder im bezug auf) kontrastmittel
JP3956402B2 (ja) * 1996-03-04 2007-08-08 日本油脂株式会社 アンホテリシンｂ運搬体
US5611344A (en) * 1996-03-05 1997-03-18 Acusphere, Inc. Microencapsulated fluorinated gases for use as imaging agents
DK0904113T3 (da) * 1996-03-05 2004-08-30 Acusphere Inc Mikroindkapslede fluorerede gasser til anvendelse som billeddannende midler
JP2947158B2 (ja) * 1996-03-07 1999-09-13 昭和電工株式会社 ヘキサフルオロエタンの製造方法
WO1997035561A1 (en) 1996-03-28 1997-10-02 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved liposome compositions
ATE345682T1 (de) * 1996-05-01 2006-12-15 Imarx Pharmaceutical Corp In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
US5837221A (en) * 1996-07-29 1998-11-17 Acusphere, Inc. Polymer-lipid microencapsulated gases for use as imaging agents
EP0938299A4 (de) * 1996-08-19 2001-01-17 Vivorx Pharmaceuticals Inc Verfahren zur herstellung von proteinpartikeln zur verabreichung pharmakologischer stoffe
ES2208946T3 (es) * 1996-08-23 2004-06-16 Sequus Pharmaceuticals, Inc. Liposomas que contienen un compuesto de cisplatino.
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
US5846517A (en) 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
DE69737915T2 (de) 1996-09-11 2008-03-13 Bristol-Myers Squibb Medical Imaging, Inc. Verfahren zur diagnostischen Bilderzeugung der Nierenregion unter Verwendung eines Kontrastmittels und eines Vasodilators
WO1998013024A2 (en) * 1996-09-27 1998-04-02 Hyal Pharmaceutical Corporation Hyaluronic drug delivery system
EE03749B1 (et) * 1996-10-21 2002-06-17 Nycomed Imaging As Kombineeritud preparaat samaaegseks, eraldi või järjestikuseks kasutamiseks kontrastainena ultrahelikujutamisel
DE19648664A1 (de) * 1996-11-14 1998-05-28 Schering Ag Wirkstoffhaltige Mikropartikel, diese enthaltende Mittel, deren Verwendung zur ultraschallgesteuerten Freisetzung von Wirkstoffen sowie Verfahren zu deren Herstellung
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
GB9701237D0 (en) * 1997-01-22 1997-03-12 Nycomed Imaging As Improvements in or relating to contrast agents
DE19709704C2 (de) 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
US6143276A (en) 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6582392B1 (en) 1998-05-01 2003-06-24 Ekos Corporation Ultrasound assembly for use with a catheter
US6676626B1 (en) 1998-05-01 2004-01-13 Ekos Corporation Ultrasound assembly with increased efficacy
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6217886B1 (en) 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
DE69819309T2 (de) * 1997-08-12 2004-07-15 Bracco Research S.A. Verabreichbare formulierugen und ihre anwendung in mri
US6548047B1 (en) * 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
JP2001517692A (ja) * 1997-09-29 2001-10-09 インヘール セラピューティック システムズ， インコーポレイテッド ネブライザにおける使用のための安定化調製物
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US7637948B2 (en) 1997-10-10 2009-12-29 Senorx, Inc. Tissue marking implant
US8668737B2 (en) 1997-10-10 2014-03-11 Senorx, Inc. Tissue marking implant
AU9550498A (en) * 1997-10-21 1999-05-10 Nycomed Imaging As Ultrasound imaging with contrast agent targeted to microvasculature and a vasodilator drug
US6123923A (en) 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
JPH11244386A (ja) * 1998-01-01 1999-09-14 Ge Yokogawa Medical Systems Ltd 血行阻止方法及び加温装置
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
US6896659B2 (en) * 1998-02-06 2005-05-24 Point Biomedical Corporation Method for ultrasound triggered drug delivery using hollow microbubbles with controlled fragility
US6161034A (en) * 1999-02-02 2000-12-12 Senorx, Inc. Methods and chemical preparations for time-limited marking of biopsy sites
JP2002511312A (ja) * 1998-04-09 2002-04-16 ナイコムド イメージング エーエス 生理学的パラメータを調べるための診断撮像における粒子状造影剤の使用
US20030078227A1 (en) * 1998-07-02 2003-04-24 Greenleaf James F. Site-directed transfection with ultrasound and cavitation nuclei
US7686763B2 (en) * 1998-09-18 2010-03-30 University Of Washington Use of contrast agents to increase the effectiveness of high intensity focused ultrasound therapy
WO2000021578A1 (en) * 1998-10-12 2000-04-20 Mallinckrodt Inc. Novel ultrasound contrast agents
US6862470B2 (en) 1999-02-02 2005-03-01 Senorx, Inc. Cavity-filling biopsy site markers
US8498693B2 (en) 1999-02-02 2013-07-30 Senorx, Inc. Intracorporeal marker and marker delivery device
US9820824B2 (en) 1999-02-02 2017-11-21 Senorx, Inc. Deployment of polysaccharide markers for treating a site within a patent
US7983734B2 (en) 2003-05-23 2011-07-19 Senorx, Inc. Fibrous marker and intracorporeal delivery thereof
US6725083B1 (en) 1999-02-02 2004-04-20 Senorx, Inc. Tissue site markers for in VIVO imaging
US8361082B2 (en) 1999-02-02 2013-01-29 Senorx, Inc. Marker delivery device with releasable plug
US7651505B2 (en) 2002-06-17 2010-01-26 Senorx, Inc. Plugged tip delivery for marker placement
US20090216118A1 (en) 2007-07-26 2009-08-27 Senorx, Inc. Polysaccharide markers
US7238368B2 (en) 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
CN1244376C (zh) 1999-04-23 2006-03-08 阿尔萨公司 可释放的键和含有该键的组合物
US6575991B1 (en) 1999-06-17 2003-06-10 Inrad, Inc. Apparatus for the percutaneous marking of a lesion
US6572840B1 (en) 1999-07-28 2003-06-03 Bristol-Myers Squibb Pharma Company Stable microbubbles comprised of a perfluoropropane encapsulated lipid moiety for use as an ultrasound contrast agent
EP1202670A4 (de) * 1999-08-13 2004-11-10 Point Biomedical Corp Hohle mikrokugeln mit kontrollierter zerbrechlichkeit zur medizinischen verwendung
US7510536B2 (en) 1999-09-17 2009-03-31 University Of Washington Ultrasound guided high intensity focused ultrasound treatment of nerves
US7520856B2 (en) * 1999-09-17 2009-04-21 University Of Washington Image guided high intensity focused ultrasound device for therapy in obstetrics and gynecology
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
AU2619301A (en) 1999-10-25 2001-06-06 Therus Corporation Use of focused ultrasound for vascular sealing
US6626855B1 (en) 1999-11-26 2003-09-30 Therus Corpoation Controlled high efficiency lesion formation using high intensity ultrasound
US7897140B2 (en) * 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
WO2001049266A2 (en) * 1999-12-30 2001-07-12 Gwathemy Judith K Iron chelator delivery system
DE60139112D1 (de) * 2000-03-06 2009-08-13 Boston Scient Ltd Unter ultralschall sichtbare embolisierende substanzen
US20020012998A1 (en) * 2000-03-29 2002-01-31 Igor Gonda Cationic liposomes
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
AU6124601A (en) 2000-05-10 2001-11-20 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
EP2279757A3 (de) 2000-06-02 2011-08-03 Bracco Suisse SA Arzneimitteln zum Targeting von Endothelzellen
EP1292285A4 (de) * 2000-06-02 2009-07-22 Eisai Corp North America Darreichungssystem für bioaktive stoffe
US6589557B2 (en) * 2000-06-15 2003-07-08 Acusphere, Inc. Porous celecoxib matrices and methods of manufacture thereof
US6800297B2 (en) 2000-06-15 2004-10-05 Acusphere, Inc. Porous COX-2 inhibitor matrices and methods of manufacture thereof
CA2411826A1 (en) * 2000-06-16 2001-12-27 Sloan-Kettering Institute For Cancer Research Liposomal encapsulation of chelated actinium-225 and uses thereof
US6599441B1 (en) * 2000-07-18 2003-07-29 Emerald Biostructures, Inc. Crystallization solutions
US7311893B2 (en) * 2000-07-25 2007-12-25 Neurochem (International) Limited Amyloid targeting imaging agents and uses thereof
CA2775170C (en) 2000-11-20 2017-09-05 Senorx, Inc. An intracorporeal marker delivery system for marking a tissue site
JP4623931B2 (ja) * 2000-12-07 2011-02-02 エンセラデュス、ファーマシューティカルズ、ベスローテン、フェンノートシャップ 炎症性疾患の治療用組成物
US7179449B2 (en) * 2001-01-30 2007-02-20 Barnes-Jewish Hospital Enhanced ultrasound detection with temperature-dependent contrast agents
US20030211045A1 (en) * 2001-02-05 2003-11-13 Danuta Leszcyznska Magnetoliposome composition for targeted treatment of biological tissue and associated methods
WO2002078611A2 (en) * 2001-03-30 2002-10-10 Drexel University Echogenic polymer microcapsules and nanocapsules and methods for production and use thereof
US7897141B2 (en) * 2002-04-01 2011-03-01 Drexel University Echogenic polymer microcapsules and nanocapsules and methods for production and use thereof
JP4426288B2 (ja) * 2001-07-10 2010-03-03 ソノジーン，リミテッド ライアビリティー カンパニー 肝臓へのｄｎａのトランスフェクションの増強
US20030215391A1 (en) * 2001-07-19 2003-11-20 Carlos Rabito Fluorescent agents for real-time measurement of organ function
US20030044354A1 (en) * 2001-08-16 2003-03-06 Carpenter Alan P. Gas microsphere liposome composites for ultrasound imaging and ultrasound stimulated drug release
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
US20050065118A1 (en) * 2001-10-16 2005-03-24 Jing Wang Organosulfur inhibitors of tyrosine phosphatases
EP1453425B1 (de) 2001-12-03 2006-03-08 Ekos Corporation Katheter mit mehreren ultraschall-abstrahlenden teilen
JP2005514393A (ja) 2001-12-19 2005-05-19 ネクター セラピューティクス アミノグリコシドの肺への供給
US6993394B2 (en) 2002-01-18 2006-01-31 Calfacion Corporation System method and apparatus for localized heating of tissue
US6850804B2 (en) 2002-01-18 2005-02-01 Calfacior Corporation System method and apparatus for localized heating of tissue
US7048756B2 (en) 2002-01-18 2006-05-23 Apasara Medical Corporation System, method and apparatus for evaluating tissue temperature
US7407778B2 (en) * 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
US7700074B2 (en) * 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
EP1587944A4 (de) * 2002-03-01 2007-03-21 Dyax Corp Kdr und vegf/kdr-bindende peptide und ihre diagnostische und therapeutische veranwendung bei der diagnose und therapie
JP2006514915A (ja) 2002-03-01 2006-05-18 ダイアックス、コープ Ｋｄｒおよびｖｅｇｆ／ｋｄｒ結合ペプチドならびに診断および治療におけるその使用
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7985402B2 (en) * 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US7666979B2 (en) * 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
US20050250700A1 (en) * 2002-03-01 2005-11-10 Sato Aaron K KDR and VEGF/KDR binding peptides
US20040076586A1 (en) * 2002-03-28 2004-04-22 Reinhard Koening Compositions and methods for delivering pharmaceutically active agents using nanoparticulates
US7462366B2 (en) 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
US7094369B2 (en) * 2002-03-29 2006-08-22 Scimed Life Systems, Inc. Processes for manufacturing polymeric microspheres
US8226629B1 (en) 2002-04-01 2012-07-24 Ekos Corporation Ultrasonic catheter power control
DE10214983A1 (de) * 2002-04-04 2004-04-08 TransMIT Gesellschaft für Technologietransfer mbH Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen
AU2003234090A1 (en) * 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for pulmonary administration
WO2003086443A1 (en) * 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
US8829198B2 (en) * 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
EP1371362A1 (de) * 2002-06-12 2003-12-17 Universiteit Utrecht Holding B.V. Zusammensetzung zur Behandlung entzündlicher Erkrankungen
US20050152962A1 (en) * 2002-06-12 2005-07-14 Metselaar Josbert M. Composition for treatment of inflammatory disorders
CA2492339A1 (en) 2002-06-12 2003-12-24 Boston Scientific Limited Bulking agents
EP1517684B1 (de) 2002-06-27 2009-07-22 Health Research, Inc. Fluorinierte chlorin und bacteriochlorin photosensitizer für fotodynamische therapie
EP2036908A3 (de) * 2002-07-02 2009-05-13 Health Research, INC. Effiziente Synthese von Pyropheophorbid-A-Derivaten
US7842377B2 (en) 2003-08-08 2010-11-30 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US20040076582A1 (en) * 2002-08-30 2004-04-22 Dimatteo Kristian Agent delivery particle
EP1393720A1 (de) * 2002-08-27 2004-03-03 Universiteit Utrecht Vesikel enthaltend Corticosteroide zur Behandlung von Krebs
US8012454B2 (en) 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization
US7198867B2 (en) * 2002-09-17 2007-04-03 Diffusion Science, Inc. Electrochemical generation, storage and reaction of hydrogen and oxygen
US6921371B2 (en) 2002-10-14 2005-07-26 Ekos Corporation Ultrasound radiating members for catheter
US7883490B2 (en) 2002-10-23 2011-02-08 Boston Scientific Scimed, Inc. Mixing and delivery of therapeutic compositions
US20060036158A1 (en) 2003-11-17 2006-02-16 Inrad, Inc. Self-contained, self-piercing, side-expelling marking apparatus
WO2004060343A1 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Antibody-containing particles and compositions
SI2949658T1 (sl) 2003-03-03 2018-10-30 Dyax Corp. Peptidi, ki specifično vežejo HGF receptor (cMet) in njihove uporabe
US20040258761A1 (en) * 2003-03-20 2004-12-23 Wheatley Margaret A. Polymer-based microcapsules and nanocapsules for diagnostic imaging and drug delivery and methods for their production
US20060198882A1 (en) * 2003-03-21 2006-09-07 Yechezkel Barenholz Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer
WO2004099162A1 (en) * 2003-04-30 2004-11-18 Ricerca Biosciences, Llc. Polycyclic diazodioxide-based bcl-2 protein antagonist
US20040242886A1 (en) * 2003-04-30 2004-12-02 Sandeep Gupta Monocyclic diazodioxide based Bcl-2 protein antagonists related applications
BRPI0410348A (pt) * 2003-05-14 2006-05-30 Torreypines Therapeutics Inc compostos e usos dos mesmos na modulação de amilóide-beta
US7877133B2 (en) 2003-05-23 2011-01-25 Senorx, Inc. Marker or filler forming fluid
WO2004110963A2 (en) * 2003-05-29 2004-12-23 Pettegrew Jay W Glycerophosphocholine and its derivatives for medical imaging neuropsychiatric disorders
US20060257842A1 (en) * 2003-05-29 2006-11-16 Pettegrew Jay W Cryopreservation media and molecules
US20100331380A1 (en) * 2009-06-29 2010-12-30 Esposito Luke A Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies
US8916598B2 (en) 2003-05-30 2014-12-23 Proteotech Inc Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
US7057100B2 (en) * 2003-06-26 2006-06-06 The J.C. Robinson Seed Co. Inbred corn line W23129
US7358226B2 (en) * 2003-08-27 2008-04-15 The Regents Of The University Of California Ultrasonic concentration of drug delivery capsules
US7976823B2 (en) 2003-08-29 2011-07-12 Boston Scientific Scimed, Inc. Ferromagnetic particles and methods
US20050106101A1 (en) * 2003-10-31 2005-05-19 Ajay Purohit Novel chemical agents comprising an adenosine moiety or an adenosine analog moiety and an imaging moiety and methods of their use
US7901770B2 (en) 2003-11-04 2011-03-08 Boston Scientific Scimed, Inc. Embolic compositions
US20050273002A1 (en) 2004-06-04 2005-12-08 Goosen Ryan L Multi-mode imaging marker
US9359481B2 (en) * 2003-11-26 2016-06-07 Owens Corning Intellectual Capital, Llc Thermoplastic foams and method of forming them using nano-graphite
US20080287560A1 (en) * 2004-12-31 2008-11-20 Loh Roland R Polymer foams containing multi-functional layered nano-graphite
US8568632B2 (en) * 2003-11-26 2013-10-29 Owens Corning Intellectual Capital, Llc Method of forming thermoplastic foams using nano-particles to control cell morphology
US8206299B2 (en) 2003-12-16 2012-06-26 University Of Washington Image guided high intensity focused ultrasound treatment of nerves
KR101535395B1 (ko) 2004-01-22 2015-07-08 유니버시티 오브 마이애미 국소용 코-엔자임 큐10 제형 및 그의 사용 방법
US7201737B2 (en) 2004-01-29 2007-04-10 Ekos Corporation Treatment of vascular occlusions using elevated temperatures
US7341569B2 (en) * 2004-01-30 2008-03-11 Ekos Corporation Treatment of vascular occlusions using ultrasonic energy and microbubbles
WO2005090370A1 (en) * 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
US7736671B2 (en) 2004-03-02 2010-06-15 Boston Scientific Scimed, Inc. Embolization
US8173176B2 (en) 2004-03-30 2012-05-08 Boston Scientific Scimed, Inc. Embolization
US7485283B2 (en) * 2004-04-28 2009-02-03 Lantheus Medical Imaging Contrast agents for myocardial perfusion imaging
WO2005112913A1 (en) 2004-05-20 2005-12-01 The Scripps Research Institute Transthyretin stabilization
US7311861B2 (en) 2004-06-01 2007-12-25 Boston Scientific Scimed, Inc. Embolization
US8012457B2 (en) 2004-06-04 2011-09-06 Acusphere, Inc. Ultrasound contrast agent dosage formulation
US7306716B2 (en) * 2004-06-16 2007-12-11 Access Business Group International Llc Water treatment system
US20060135773A1 (en) * 2004-06-17 2006-06-22 Semple Joseph E Trisubstituted nitrogen modulators of tyrosine phosphatases
WO2006017124A2 (en) * 2004-07-09 2006-02-16 Cengent Therapeutics, Inc. Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases
US9066679B2 (en) 2004-08-31 2015-06-30 University Of Washington Ultrasonic technique for assessing wall vibrations in stenosed blood vessels
EP1841749A1 (de) * 2004-09-02 2007-10-10 Metabasis Therapeutics, Inc. Thiazol- und thiadiazolderivate als inhibitoren von tyrosinphosphatasen
WO2006028959A2 (en) * 2004-09-03 2006-03-16 Imarx Therapeutics, Inc. Apparatus and method to prepare a microsphere-forming composition
MX2007003044A (es) * 2004-09-16 2007-08-02 Univ Washington Acoplador acustico que utiliza una almohada de agua independientemente con circulacion para enfriar un transductor.
NZ588431A (en) 2004-09-17 2012-02-24 Whitehead Biomedical Inst Using Benzimidazole or Indole compounds with a 1,2-diazole group to Inhibit Alpha-Synuclein Toxicity
US20060067889A1 (en) * 2004-09-27 2006-03-30 Light Sciences Corporation Singlet oxygen photosensitizers activated by target binding enhancing the selectivity of targeted PDT agents
JP2008515929A (ja) * 2004-10-08 2008-05-15 アルザ コーポレイション 脂質連結部分を予備形成した脂質集合体にマイクロ波を使用して挿入する方法
US8425550B2 (en) 2004-12-01 2013-04-23 Boston Scientific Scimed, Inc. Embolic coils
DK1842557T3 (da) 2004-12-22 2013-12-02 Nitto Denko Corp Lægemiddelbærer og lægemiddelbærerkit til inhibition af fibrose
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
CN100427142C (zh) * 2005-01-10 2008-10-22 重庆海扶(Hifu)技术有限公司 一种高强度聚焦超声治疗用助剂及其筛选方法
WO2006079989A2 (en) * 2005-01-28 2006-08-03 North-West University Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines
US7858183B2 (en) 2005-03-02 2010-12-28 Boston Scientific Scimed, Inc. Particles
US7727555B2 (en) 2005-03-02 2010-06-01 Boston Scientific Scimed, Inc. Particles
US8153435B1 (en) 2005-03-30 2012-04-10 Tracer Detection Technology Corp. Methods and articles for identifying objects using encapsulated perfluorocarbon tracers
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
US8222257B2 (en) 2005-04-01 2012-07-17 The Regents Of The University Of California Phosphono-pent-2-en-1-yl nucleosides and analogs
EP1874197A4 (de) * 2005-04-12 2010-02-10 Ekos Corp Ultraschallkatheter mit kavitationsfördernder oberfläche
EP1714642A1 (de) * 2005-04-18 2006-10-25 Bracco Research S.A. Pharmazeutische Formulierung mit gasgefüllten Mikrokapseln zur ultraschallgesteuerten Freisetzung
US10357328B2 (en) 2005-04-20 2019-07-23 Bard Peripheral Vascular, Inc. and Bard Shannon Limited Marking device with retractable cannula
US7963287B2 (en) 2005-04-28 2011-06-21 Boston Scientific Scimed, Inc. Tissue-treatment methods
AU2005332157A1 (en) * 2005-05-23 2006-11-30 Mebiopharm Co., Ltd., Method of producing liposomes containing gas enclosed therein
WO2006129099A1 (en) * 2005-06-02 2006-12-07 Cancercure Technology As Ultrasound treatment system
WO2007002109A2 (en) * 2005-06-20 2007-01-04 The Regents Of The University Of California Multidentate pyrone-derived chelators for medicinal imaging and chelation
US9463426B2 (en) 2005-06-24 2016-10-11 Boston Scientific Scimed, Inc. Methods and systems for coating particles
US7824659B2 (en) 2005-08-10 2010-11-02 Lantheus Medical Imaging, Inc. Methods of making radiolabeled tracers and precursors thereof
WO2007021958A2 (en) 2005-08-12 2007-02-22 University Of Washington Method and apparatus for preparing organs and tissues for laparoscopic surgery
US9486274B2 (en) 2005-09-07 2016-11-08 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US9358033B2 (en) 2005-09-07 2016-06-07 Ulthera, Inc. Fluid-jet dissection system and method for reducing the appearance of cellulite
US10548659B2 (en) 2006-01-17 2020-02-04 Ulthera, Inc. High pressure pre-burst for improved fluid delivery
US9011473B2 (en) 2005-09-07 2015-04-21 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US8518069B2 (en) 2005-09-07 2013-08-27 Cabochon Aesthetics, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US9187608B2 (en) * 2005-09-08 2015-11-17 Owens Corning Intellectual Capital, Llc Polystyrene foam containing a modifier-free nanoclay and having improved fire protection performance
US8414494B2 (en) 2005-09-16 2013-04-09 University Of Washington Thin-profile therapeutic ultrasound applicators
WO2008051197A2 (en) * 2005-09-20 2008-05-02 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
US8016757B2 (en) 2005-09-30 2011-09-13 University Of Washington Non-invasive temperature estimation technique for HIFU therapy monitoring using backscattered ultrasound
US8052658B2 (en) 2005-10-07 2011-11-08 Bard Peripheral Vascular, Inc. Drug-eluting tissue marker
US8007509B2 (en) 2005-10-12 2011-08-30 Boston Scientific Scimed, Inc. Coil assemblies, components and methods
US8167805B2 (en) 2005-10-20 2012-05-01 Kona Medical, Inc. Systems and methods for ultrasound applicator station keeping
US8257338B2 (en) * 2006-10-27 2012-09-04 Artenga, Inc. Medical microbubble generation
US20080200864A1 (en) * 2005-12-02 2008-08-21 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US9248317B2 (en) * 2005-12-02 2016-02-02 Ulthera, Inc. Devices and methods for selectively lysing cells
US7885793B2 (en) 2007-05-22 2011-02-08 International Business Machines Corporation Method and system for developing a conceptual model to facilitate generating a business-aligned information technology solution
US20080014627A1 (en) * 2005-12-02 2008-01-17 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US20080195036A1 (en) * 2005-12-02 2008-08-14 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US20070140973A1 (en) * 2005-12-15 2007-06-21 Bristol-Myers Squibb Pharma Company Contrast agents for myocardium perfusion imaging
US8101197B2 (en) 2005-12-19 2012-01-24 Stryker Corporation Forming coils
US8152839B2 (en) 2005-12-19 2012-04-10 Boston Scientific Scimed, Inc. Embolic coils
US7947368B2 (en) 2005-12-21 2011-05-24 Boston Scientific Scimed, Inc. Block copolymer particles
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
WO2007076160A2 (en) * 2005-12-28 2007-07-05 Acidophil Llc C-10 carbamates of taxanes
US20070196462A1 (en) * 2006-01-24 2007-08-23 Imarx Therapeutics, Inc. Composition and method for neuromuscular blockade
US20070184085A1 (en) * 2006-02-03 2007-08-09 Boston Scientific Scimed, Inc. Ultrasound activated medical device
US20070184076A1 (en) * 2006-02-07 2007-08-09 Unger Evan C Liquid-filled nanodroplets for anti-cancer therapy
PL2383271T3 (pl) * 2006-03-13 2013-12-31 Kyorin Seiyaku Kk Aminochinolony jako inhibitory GSK-3
BRPI0709699A2 (pt) * 2006-03-29 2011-07-26 Foldrx Pharmaceuticals Inc inibiÇço da toxidez da alfa-sinucleina
EP2015846A2 (de) 2006-04-24 2009-01-21 Ekos Corporation Ultraschalltherapiesystem
JP2009535126A (ja) * 2006-04-27 2009-10-01 バーンズ−ジューイッシュ ホスピタル 標的組織の検出とイメージング
WO2007137236A2 (en) * 2006-05-19 2007-11-29 Drexel University Drug loaded contrast agents: combining diagnosis and therapy
EP2064243A2 (de) 2006-08-28 2009-06-03 Kyowa Hakko Kirin Co., Ltd. Antagonistische lichtspezifische menschliche monoklonale antikörper
US20070080613A1 (en) * 2006-09-20 2007-04-12 Sterlite Optical Technologies Ltd Storage and transportation device for storing and transporting optical fiber preform and precursors thereof
AU2007297597B2 (en) 2006-09-21 2013-02-21 Kyorin Pharmaceuticals Co., Ltd. Serine hydrolase inhibitors
JP2010507585A (ja) 2006-10-19 2010-03-11 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換インドール
EP2079385B1 (de) 2006-10-23 2013-11-20 C.R.Bard, Inc. Brustkennzeichner
US8414927B2 (en) 2006-11-03 2013-04-09 Boston Scientific Scimed, Inc. Cross-linked polymer particles
WO2008057604A2 (en) * 2006-11-08 2008-05-15 The Regents Of The University Of California Small molecule therapeutics, syntheses of analogues and derivatives and methods of use
WO2008073965A2 (en) 2006-12-12 2008-06-19 C.R. Bard Inc. Multiple imaging mode tissue marker
ES2432572T3 (es) 2006-12-18 2013-12-04 C.R. Bard, Inc. Marcador de biopsia con propiedades de obtención de imágenes generadas in situ
US20080146605A1 (en) 2006-12-19 2008-06-19 Auspex Pharmaceuticals, Inc. Preparation and utility of ccr5 inhibitors
WO2008079371A1 (en) * 2006-12-22 2008-07-03 Encysive Pharmaceuticals, Inc. Modulators of c3a receptor and methods of use thereof
US10182833B2 (en) 2007-01-08 2019-01-22 Ekos Corporation Power parameters for ultrasonic catheter
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
PL2144604T3 (pl) * 2007-02-28 2012-02-29 Conatus Pharmaceuticals Inc Sposoby leczenia przewlekłego zapalenia wątroby typu C z zastosowaniem RO 113-0830
EP3103790B1 (de) 2007-03-15 2018-05-09 Auspex Pharmaceuticals, Inc. Substituiertes phenethylamine mit serotoninergischer und/oder norepinephrinergischer aktivität
CA2680825C (en) 2007-03-22 2013-10-29 Cytotech Labs, Llc Topical formulations having enhanced bioavailability
US20080242752A1 (en) * 2007-03-28 2008-10-02 Yadollah Delaviz Polystyrene foams incorporating nanographite and HFC-134
TWI407971B (zh) * 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
US20090074862A1 (en) * 2007-04-13 2009-03-19 Luigi Schioppi Low-dose doxepin formulations and methods of making and using the same
US7892776B2 (en) 2007-05-04 2011-02-22 The Regents Of The University Of California Screening assay to identify modulators of protein kinase A
US9044568B2 (en) 2007-06-22 2015-06-02 Ekos Corporation Method and apparatus for treatment of intracranial hemorrhages
CN101801188A (zh) * 2007-07-12 2010-08-11 特拉加拉医药品公司 治疗癌症、肿瘤和肿瘤相关性疾病的方法和组合物
AU2008299903B2 (en) * 2007-09-11 2013-08-29 Kyorin Pharmaceutical Co., Ltd Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors
CN101855229A (zh) 2007-09-12 2010-10-06 埃迪威克斯生物科学公司 作为gsk-3抑制剂的螺环状氨基喹诺酮
US20090264421A1 (en) * 2007-10-05 2009-10-22 Bible Keith C Methods and Compositions for Treating Cancer
US8439940B2 (en) 2010-12-22 2013-05-14 Cabochon Aesthetics, Inc. Dissection handpiece with aspiration means for reducing the appearance of cellulite
CA2706465A1 (en) 2007-11-21 2009-05-28 Pharmaxis Ltd. Haloallylamine inhibitors of ssao/vap-1 and uses therefor
JP2011506432A (ja) * 2007-12-10 2011-03-03 エピターゲット・アーエス 非ラメラ形成脂質を含む音響感受性薬物送達粒子
US20090151241A1 (en) * 2007-12-14 2009-06-18 Dressler Lawrence V Method for producing algae in photobioreactor
US8311610B2 (en) 2008-01-31 2012-11-13 C. R. Bard, Inc. Biopsy tissue marker
DK2257315T3 (da) 2008-02-29 2020-01-27 Lantheus Medical Imaging Inc Kontrastmidler til anvendelser omfattende perfusionsbilleddannelse
WO2009111611A2 (en) * 2008-03-05 2009-09-11 Proteotech Inc. Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
MX2010010172A (es) 2008-03-17 2010-11-25 Ambit Biosciences Corp Derivados de quinazolina como moduladores de quinasa raf y metodos de uso de los mismos.
EP2271325A4 (de) 2008-04-11 2011-11-09 Cytotech Labs Llc Verfahren und verfwendung zur einleitung von apoptose bei krebszellen
US8197857B2 (en) * 2008-06-06 2012-06-12 Dressler Lawrence V Method for eliminating carbon dioxide from waste gases
GB0811856D0 (en) 2008-06-27 2008-07-30 Ucl Business Plc Magnetic microbubbles, methods of preparing them and their uses
US20120034157A1 (en) * 2010-08-03 2012-02-09 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Artificial cells
CN101658533A (zh) * 2008-08-29 2010-03-03 首都医科大学宣武医院 抗肿瘤药物的干细胞递送
US9327061B2 (en) 2008-09-23 2016-05-03 Senorx, Inc. Porous bioabsorbable implant
US9192685B2 (en) * 2008-10-07 2015-11-24 Bracco Suisse S.A. Targeting construct comprising anti-polymer antibody and contrast/therapeutic agents binding to the same
ES2560515T3 (es) 2008-12-30 2016-02-19 C.R. Bard, Inc. Dispositivo de administración de marcador para la colocación del marcador de tejido
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
US20100204570A1 (en) * 2009-02-06 2010-08-12 Paul Lubock Anchor markers
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
MY159327A (en) * 2009-02-27 2016-12-25 Ambit Biosciences Corp Jak kinase modulating quinazoline derivatives and methods of use thereof
US8193372B2 (en) 2009-03-04 2012-06-05 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole HCV polymerase inhibitors
BRPI1008974A2 (pt) * 2009-03-11 2017-06-06 Kyorin Seiyaku Kk composto, composição farmacêutica, e, método para tratar, prevenir ou melhorar uma doença mediada com gsk-3
JP2012520314A (ja) 2009-03-11 2012-09-06 アムビト ビオスシエンセス コルポラチオン 癌治療のためのインダゾリルアミノピロロトリアジンとタキサンの併用
AU2010226326B2 (en) * 2009-03-20 2015-11-26 Incube Labs, Llc Solid drug delivery apparatus, formulations and methods of use
NZ595372A (en) 2009-03-27 2013-11-29 Vetdc Inc Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
WO2010120368A2 (en) 2009-04-15 2010-10-21 Lantheus Medical Imaging, Inc. Stabilization of radiopharmaceutical compositions using ascorbic acid
DK2421829T3 (en) 2009-04-22 2016-01-04 Axikin Pharmaceuticals Inc 2,5-disubstituted aryl sulfonamide CCR3 antagonists
PE20150759A1 (es) 2009-04-22 2015-05-15 Axikin Pharmaceuticals Inc Antagonistas ccr3 arilsulfonamida
PE20150925A1 (es) 2009-04-22 2015-06-14 Axikin Pharmaceuticals Inc Antagonistas de ccr3 de arilsulfonamida 2,5-disustituida
KR20120034649A (ko) 2009-05-11 2012-04-12 버그 바이오시스템즈, 엘엘씨 환경대사적 전환인자（조효소 ｑ１０）를 사용한 질환의 치료 방법
DE102009031274A1 (de) 2009-06-30 2011-01-13 Justus-Liebig-Universität Giessen Liposomen zur pulmonalen Applikation
WO2011003870A2 (en) 2009-07-06 2011-01-13 Creabilis S.A. Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
EP2451802A1 (de) 2009-07-07 2012-05-16 Pathway Therapeutics, Inc. Pyrimidinyl- und 1,3,5-triazinyl-benzimidazole und ihre verwendung in der krebstherapie
JP5905387B2 (ja) 2009-07-08 2016-04-20 ホープ メディカル エンタープライゼズ，インコーポレイテッド ディービーエー ホープ ファーマシュティカルズＨｏｐｅ Ｍｅｄｉｃａｌ Ｅｎｔｅｒｐｒｉｓｅｓ，Ｉｎｃ．Ｄｂａ Ｈｏｐｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ チオ硫酸ナトリウムを含有する薬学的組成物
US8404728B2 (en) 2009-07-30 2013-03-26 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
WO2011017389A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
US11096708B2 (en) 2009-08-07 2021-08-24 Ulthera, Inc. Devices and methods for performing subcutaneous surgery
US9358064B2 (en) 2009-08-07 2016-06-07 Ulthera, Inc. Handpiece and methods for performing subcutaneous surgery
MX2012001974A (es) 2009-08-19 2012-04-11 Ambit Biosciences Corp Compuestos de biarilo y metodos de uso de los mismos.
WO2011029094A2 (en) 2009-09-04 2011-03-10 The University Of North Carolina At Chapel Hill Systems, methods, and computer readable media for high- frequency contrast imaging and image-guided therapeutics
WO2011034892A2 (en) 2009-09-15 2011-03-24 The Trustees Of Columbia University In The City Of New York Systems, methods, and devices for microbubbles
US8986231B2 (en) 2009-10-12 2015-03-24 Kona Medical, Inc. Energetic modulation of nerves
US8469904B2 (en) 2009-10-12 2013-06-25 Kona Medical, Inc. Energetic modulation of nerves
US20110092880A1 (en) 2009-10-12 2011-04-21 Michael Gertner Energetic modulation of nerves
US20160059044A1 (en) 2009-10-12 2016-03-03 Kona Medical, Inc. Energy delivery to intraparenchymal regions of the kidney to treat hypertension
US8295912B2 (en) 2009-10-12 2012-10-23 Kona Medical, Inc. Method and system to inhibit a function of a nerve traveling with an artery
US8517962B2 (en) 2009-10-12 2013-08-27 Kona Medical, Inc. Energetic modulation of nerves
US9119951B2 (en) 2009-10-12 2015-09-01 Kona Medical, Inc. Energetic modulation of nerves
US8986211B2 (en) 2009-10-12 2015-03-24 Kona Medical, Inc. Energetic modulation of nerves
US9174065B2 (en) 2009-10-12 2015-11-03 Kona Medical, Inc. Energetic modulation of nerves
US20110118600A1 (en) 2009-11-16 2011-05-19 Michael Gertner External Autonomic Modulation
US8470817B2 (en) * 2009-10-26 2013-06-25 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
WO2011057214A2 (en) 2009-11-09 2011-05-12 Neurogenetic Pharmaceuticals, Inc. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
WO2011069002A1 (en) 2009-12-02 2011-06-09 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
SG181797A1 (en) 2009-12-18 2012-07-30 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
WO2011079313A1 (en) * 2009-12-23 2011-06-30 Map Pharmaceuticals, Inc. Novel ergoline analogs
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
CN109200296B (zh) 2010-02-08 2021-12-14 兰休斯医疗成像公司 用于合成显像剂和其中间体的方法和装置
EP2542542B1 (de) 2010-03-02 2015-04-22 Axikin Pharmaceuticals, Inc. Isotopisch angereicherte arylsulfonamid-ccr3-antagonisten
WO2011112689A2 (en) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
NZ602057A (en) * 2010-03-12 2015-06-26 Berg Pharma Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
JP5818873B2 (ja) 2010-03-17 2015-11-18 アクシキン ファーマシューティカルズ インコーポレーテッド アリールスルホンアミドｃｃｒ３アンタゴニスト
JP5735488B2 (ja) * 2010-04-09 2015-06-17 株式会社日立製作所 超音波診断治療装置
WO2011150198A1 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
WO2011150201A2 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
MX2012013879A (es) 2010-06-01 2013-04-03 Biotheryx Inc Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
CN103153309A (zh) 2010-06-01 2013-06-12 拜欧赛里克斯公司 使用6-环己基-1-羟基-4-甲基-2(1h)-吡啶酮治疗血液恶性肿瘤的方法
AU2011265047B2 (en) 2010-06-07 2014-10-23 Novomedix, Llc Furanyl compounds and the use thereof
US20140200270A1 (en) 2013-01-11 2014-07-17 Summa Health System Vitamins c and k for treating polycystic diseases
CA2805745C (en) 2010-07-19 2019-01-15 Summa Health System Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
ITPI20100095A1 (it) * 2010-07-28 2012-01-29 Giuseppe Sabino Un mezzo di contrasto ecografico antigene-specifico, un procedimento per la sua preparazione e suoi usi.
WO2012030912A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
WO2012030913A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
JP5872558B2 (ja) 2010-09-01 2016-03-01 アムビト ビオスシエンセス コルポラチオン ピラゾリルアミノキナゾリンの臭化水素酸塩
EP2611502A1 (de) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Adenosin-a3-rezeptormodulierende verbindungen und ihre verwendung
US20130317045A1 (en) 2010-09-01 2013-11-28 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
EP2611809A1 (de) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Azolopyridin- und azolopyrimidinverbindungen sowie verfahren zu ihrer verwendung
CN103298805A (zh) 2010-09-01 2013-09-11 埃姆比特生物科学公司 喹唑啉化合物及其使用方法
US20130225615A1 (en) 2010-09-01 2013-08-29 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
US20130225614A1 (en) 2010-09-01 2013-08-29 Ambit Biosciences Corporation 4-azolylaminoquinazoline derivatives and methods of use thereof
WO2012030944A2 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinoline and isoquinoline compounds and methods of use thereof
WO2012044641A1 (en) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2012048335A2 (en) * 2010-10-08 2012-04-12 The University Of North Carolina At Chapel Hill Formulation of acoustically activatable particles having low vaporization energy and methods for using same
AU2011313906B2 (en) 2010-10-11 2015-08-13 Axikin Pharmaceuticals, Inc. Salts of arylsulfonamide CCR3 antagonists
WO2012078649A1 (en) 2010-12-06 2012-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
EP2668210B1 (de) 2011-01-26 2020-06-17 Celldex Therapeutics, Inc. Anti-kit-antikörper und ihre verwendungen
WO2012106299A1 (en) 2011-01-31 2012-08-09 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
WO2012109398A1 (en) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
EP2691388A1 (de) 2011-03-28 2014-02-05 MEI Pharma, Inc. (kondensierte arylamino- und heterocyclylamino-)pyrimidynyl und 1,3,5-triazinyl-benzimidazole, pharmazeutische zusammensetzungen daraus und ihre verwendung zur behandlung von proliferativen erkrankungen
EP2691389A1 (de) 2011-03-28 2014-02-05 MEI Pharma, Inc. (alpha-substituierte cycloalkylamino- und) heterocyclylamino-)pyrimidinyl- und 1,3,5-triazinyl-benzimidazole, pharmazeutische zusammensetzungen daraus und ihre verwendung zur behandlung von proliferativen erkrankungen
WO2012135160A1 (en) 2011-03-28 2012-10-04 Pathway Therapeutics Inc. (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
ES2762451T3 (es) 2011-04-04 2020-05-25 Berg Llc Tratamiento de tumores del sistema nervioso central con coenzima Q10
WO2012136813A2 (en) 2011-04-07 2012-10-11 Universitetet I Oslo Agents for medical radar diagnosis
SG10201605008TA (en) 2011-06-17 2016-07-28 Berg Llc Inhalable pharmaceutical compositions
CN103827113A (zh) 2011-06-23 2014-05-28 Map药物公司 新型氟麦角碱类似物
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
US8822549B2 (en) * 2011-10-13 2014-09-02 Jennifer L. Johnson Buffered oxygen therapeutic
WO2013056070A2 (en) 2011-10-14 2013-04-18 Ambit Biosciences Corporation Heterocyclic compounds and methods of use thereof
US9057712B1 (en) 2011-10-27 2015-06-16 Copilot Ventures Fund Iii Llc Methods of delivery of encapsulated perfluorocarbon taggants
CA2859173A1 (en) 2011-12-19 2013-06-27 Map Pharmaceuticals, Inc. Novel iso-ergoline derivatives
WO2013095708A1 (en) 2011-12-21 2013-06-27 Map Pharmaceuticals, Inc. Novel neuromodulatory compounds
WO2013130600A1 (en) 2012-02-29 2013-09-06 Ambit Biosciences Corporation Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
CN104302640A (zh) 2012-03-16 2015-01-21 埃克希金医药品有限公司 3,5-二氨基吡唑激酶抑制剂
SI2844637T1 (en) 2012-05-02 2018-07-31 Boehringer Ingelheim International Gmbh Substituted 3-haloaliline SSAO inhibitors and their use
EP2861562B1 (de) 2012-06-14 2018-05-09 Mayo Foundation For Medical Education And Research Pyrazolderivate als hemmer von stat3
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
JP6420761B2 (ja) * 2012-06-26 2018-11-07 ジーイー・ヘルスケア・アクスイェ・セルスカプ 気体マイクロバブルを含む組成物の調製
US9334332B2 (en) 2012-07-25 2016-05-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
CN103565745A (zh) 2012-08-10 2014-02-12 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
AU2013312420A1 (en) 2012-09-07 2015-02-26 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide CCR3 antagonists
WO2014055647A1 (en) 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
WO2014055832A1 (en) 2012-10-04 2014-04-10 The University Of North Carolina At Chapel Hill Methods and systems for using encapsulated microbubbles to process biological samples
CA2890177A1 (en) 2012-11-08 2014-05-15 Summa Health System Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
ES2689921T3 (es) 2012-11-30 2018-11-16 Novomedix, Llc Biarilsulfonamidas sustituidas y sus usos
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
SG11201504931SA (en) 2012-12-21 2015-07-30 Map Pharmaceuticals Inc Novel methysergide derivatives
US9101745B2 (en) 2013-03-14 2015-08-11 Sonogene Llc Sonochemical induction of ABCA1 expression and compositions therefor
WO2014145443A2 (en) 2013-03-15 2014-09-18 The Board Of Regents Of The University Of Texas System Liquids rich in noble gas and methods of their preparation and use
EA032775B1 (ru) 2013-04-08 2019-07-31 Берг Ллк Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10
SG11201509982UA (de) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
CN105683182A (zh) 2013-08-30 2016-06-15 埃姆比特生物科学公司 联芳基乙酰胺化合物及其使用方法
JP6595478B2 (ja) 2013-09-04 2019-10-23 バーグ エルエルシー コエンザイムｑ１０の連続注入によるがんの治療方法
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
US20160229866A1 (en) 2013-09-20 2016-08-11 Idenix Pharmaceuticals Inc. Hepatitis c virus inhibitors
USD715442S1 (en) 2013-09-24 2014-10-14 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD716450S1 (en) 2013-09-24 2014-10-28 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD716451S1 (en) 2013-09-24 2014-10-28 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD715942S1 (en) 2013-09-24 2014-10-21 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
JP6870988B2 (ja) 2014-02-24 2021-05-19 セルジーン コーポレイション 神経細胞増幅及び中枢神経系障害治療のためのセレブロンの活性化因子の使用方法
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP3114122A1 (de) 2014-03-05 2017-01-11 Idenix Pharmaceuticals LLC Feste formen einer flaviviridae-virus-hemmerverbindung und salze davon
CA2943220C (en) 2014-03-20 2024-01-16 Capella Therapeutics, Inc. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
US10202398B2 (en) 2014-03-20 2019-02-12 Capella Therapeutics, Inc. Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
WO2015143357A2 (en) * 2014-03-21 2015-09-24 Boston Scientific Scimed, Inc. Devices and methods for treating a lung
AU2015259471A1 (en) 2014-05-12 2016-11-24 Conatus Pharmaceuticals, Inc. Treatment of the complications of chronic liver disease with caspase inhibitors
MA47849A (fr) 2014-05-28 2020-01-29 Agenus Inc Anticorps anti-gitr et leurs procédés d'utilisation
US9527815B2 (en) 2014-06-18 2016-12-27 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
GB201411423D0 (en) * 2014-06-26 2014-08-13 Ge Healthcare As Lipid sterilisation method
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
WO2016025129A1 (en) 2014-08-14 2016-02-18 Alhamadsheh Mamoun M Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
SG10201902137PA (en) 2014-09-12 2019-04-29 Tobira Therapeutics Inc Cenicriviroc combination therapy for the treatment of fibrosis
US20170354639A1 (en) 2014-10-24 2017-12-14 Biogen Ma Inc. Diterpenoid derivatives and methods of use thereof
US10925579B2 (en) 2014-11-05 2021-02-23 Otsuka Medical Devices Co., Ltd. Systems and methods for real-time tracking of a target tissue using imaging before and during therapy delivery
US10500227B2 (en) * 2014-12-03 2019-12-10 University Of Cincinnati Bioactive gas-encapsulated echogenic liposomes and methods for treating cardiovascular disease
EP3229838B1 (de) 2014-12-11 2020-09-09 Pierre Fabre Medicament Anti-c10orf54-antikörper und verwendungen davon
EP3789039A1 (de) 2014-12-22 2021-03-10 The Rockefeller University Anti-mertk-antikörper und verwendungen davon
MY191736A (en) 2014-12-23 2022-07-13 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
MX2017008721A (es) 2014-12-31 2017-11-17 Lantheus Medical Imaging Inc Composiciones de microesferas de gas encapsulado en lipidos y metodos relacionados.
US9657020B2 (en) 2015-01-20 2017-05-23 Xoc Pharmaceuticals, Inc. Ergoline compounds and uses thereof
BR112017015510A2 (pt) 2015-01-20 2018-01-30 Xoc Pharmaceuticals Inc composto de fórmula estrutural (i), método de tratamento e/ou prevenção, método de agonização do receptor d2 em um indivíduo, método de antagonização do receptor d3 em um indivíduo, método de agonização do receptor 5-ht1d em um indivíduo, método de agonização do receptor 5-ht1a em um indivíduo, método de agonização seletiva do receptor 5-ht1d em vez do receptor 5-ht1b em um indivíduo, método de agonização seletiva do re-ceptor 5-ht2c em vez do receptor 5-ht2a ou 5-ht2b em um indivíduo, método de agonização do receptor 5-ht2c em um indivíduo, método de fornecimento de atividade antagonista funcional no receptor 5-ht2b ou receptor 5-ht7, e, método de fornecimento de atividade antagonista funcional nos receptores adrenérgicos em um indivíduo
CN107428749B (zh) 2015-01-28 2020-07-24 上海复旦张江生物医药股份有限公司 取代的咪唑并[1,2-α]吡啶-2-基胺化合物及其药物组合物和使用方法
WO2016139482A1 (en) 2015-03-03 2016-09-09 Kymab Limited Antibodies, uses & methods
SG10201913500TA (en) 2015-05-29 2020-03-30 Agenus Inc Anti-ctla-4 antibodies and methods of use thereof
EP3307388B1 (de) 2015-06-10 2022-06-22 Ekos Corporation Ultraschallkatheter
CN104984338A (zh) * 2015-06-23 2015-10-21 重庆医科大学 笑气作为细胞内超声空化效应增强剂的应用
KR20180015260A (ko) 2015-06-23 2018-02-12 뉴로크린 바이오사이언시즈 인코퍼레이티드 신경계 질환 또는 장애를 치료하기 위한 vmat2 억제제
EA201890630A1 (ru) 2015-09-01 2018-10-31 Эйдженус Инк. Антитела против pd-1 и способы их применения
CN115322188A (zh) 2015-10-30 2022-11-11 纽罗克里生物科学有限公司 Valbenazine盐及其多晶形物
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
HUE059065T2 (hu) 2015-12-23 2022-10-28 Neurocrine Biosciences Inc Szintetikus eljárás (S)-(2R,3R,11BR)-3-izobutil-9,10-dimetoxi-2,3,4,6,7,11B-hexahidro-1H-pirido [2,1-A]izokinolin-2-il-2-amino-3-metilbutanoát-di(4-metilbenzolszulfonát) elõállítására
CN108697663A (zh) 2015-12-31 2018-10-23 科内图斯医药公司 在肝病治疗中使用胱天蛋白酶抑制剂的方法
AR107320A1 (es) 2016-01-08 2018-04-18 Celgene Corp Formas sólidas de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoindolin-5-il)metil)-2,2-difluoroacetamida y sus composiciones farmacéuticas y usos
WO2017120422A1 (en) 2016-01-08 2017-07-13 Celgene Corporation Antiproliferative compounds, and their pharmaceutical compositions and uses
US10960013B2 (en) 2016-03-04 2021-03-30 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
JP2019513151A (ja) 2016-03-08 2019-05-23 ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． カンプトテシン誘導体及びその使用
US10064855B2 (en) 2016-03-08 2018-09-04 Los Gatos Pharmaceuticals, Inc. Composite nanoparticles and uses thereof
EP3442940A1 (de) 2016-04-11 2019-02-20 Clexio Biosciences Ltd. Deuterierte ketaminderivate
WO2017180794A1 (en) 2016-04-13 2017-10-19 Skyline Antiinfectives, Inc. Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams
KR20180133527A (ko) 2016-05-04 2018-12-14 랜티우스 메디컬 이메징, 인크. 초음파 조영제의 제조 방법 및 장치
ES2939373T3 (es) 2016-05-13 2023-04-21 Pasteur Institut Inhibición de los receptores de acetilcolina nicotínicos beta-2 para tratar la patología de la enfermedad de Alzheimer
TWI753910B (zh) 2016-05-16 2022-02-01 美商拜歐斯瑞克斯公司 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
MX2018014387A (es) 2016-05-27 2019-03-14 Agenus Inc Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
US9789210B1 (en) 2016-07-06 2017-10-17 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
KR20190039937A (ko) 2016-07-08 2019-04-16 스태튼 바이오테크놀로지 비.브이. 항-ApoC3 항체 및 이의 사용 방법
WO2018035281A1 (en) 2016-08-17 2018-02-22 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
JP2019529419A (ja) 2016-09-19 2019-10-17 エムイーアイ ファーマ，インク． 併用療法
TW202246349A (zh) 2016-10-11 2022-12-01 美商艾吉納斯公司 抗ｌａｇ－３抗體及其使用方法
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
WO2018083538A1 (en) 2016-11-07 2018-05-11 Neuracle Scienc3 Co., Ltd. Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
CN116987014A (zh) 2016-11-09 2023-11-03 诺沃梅迪科斯有限公司 1,1-二甲双胍的亚硝酸盐、药物组合物和使用方法
US10106521B2 (en) 2016-11-09 2018-10-23 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
US10836774B2 (en) 2016-11-30 2020-11-17 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
US10799503B2 (en) 2016-12-01 2020-10-13 Ignyta, Inc. Methods for the treatment of cancer
TW202345829A (zh) 2016-12-02 2023-12-01 美商紐羅克里生物科學有限公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
MX2019006340A (es) 2016-12-07 2019-11-07 Agenus Inc Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) y métodos de uso de los mismos.
CA3046082A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Antibodies and methods of use thereof
JP7199361B2 (ja) 2017-01-27 2023-01-05 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
MX2019009764A (es) 2017-02-17 2019-11-11 Eidos Therapeutics Inc Procesos para preparar acido 3-(3-(3,5-dimetil-1h-pirazol-4-il)pro poxi)-4- 5-fluorobenzoico (ag-10), sus compuestos intermedios, y sales del mismo.
BR112019017260A2 (pt) 2017-02-17 2020-04-14 Camris Int Inc antiveneno universal
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
US20200330590A1 (en) 2017-03-27 2020-10-22 Celgene Corporation Methods and compositions for reduction of immunogenicity
BR112019017241A2 (pt) 2017-04-13 2020-04-14 Agenus Inc anticorpos anti-cd137 e métodos de uso dos mesmos
CN110506056A (zh) 2017-04-21 2019-11-26 斯塔滕生物技术有限公司 抗apoc3抗体和其使用方法
US20200179352A1 (en) 2017-04-26 2020-06-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
EP3618863B1 (de) 2017-05-01 2023-07-26 Agenus Inc. Anti-tigit antikörper und deren verwendung
JOP20190219A1 (ar) 2017-05-09 2019-09-22 Cardix Therapeutics LLC تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
WO2018223065A1 (en) 2017-06-01 2018-12-06 Xoc Pharmaceuticals, Inc. Ergoline derivatives for use in medicine
JP7076059B2 (ja) 2017-06-27 2022-05-27 ニューラクル サイエンス カンパニー リミテッド 抗ｆａｍ１９ａ５抗体及びその用途
EP3645039A4 (de) 2017-06-27 2021-05-05 Neuracle Science Co., Ltd Verwendung von anti-fam19a5-antikörpern zur behandlung von fibrose
WO2019003164A1 (en) 2017-06-27 2019-01-03 Neuracle Science Co., Ltd. USE OF ANTI-FAM19A5 ANTIBODIES FOR THE TREATMENT OF CANCERS
EP3645044A4 (de) 2017-06-27 2021-04-28 Neuracle Science Co., Ltd Verwendung von anti-familie mit sequenzähnlichkeit 19, element-a5-antikörpern zur behandlung von glaukom
ES2953032T3 (es) 2017-09-01 2023-11-07 Univ East Carolina Métodos ex vivo para la activación de las células inmunológicas
CN111372567B (zh) 2017-09-21 2024-03-15 纽罗克里生物科学有限公司 高剂量的缬苯那嗪制剂和与其相关的组合物、方法和试剂盒
SG11202003194YA (en) 2017-10-10 2020-05-28 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
CA3080103A1 (en) 2017-10-31 2019-05-09 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
TW201929847A (zh) 2018-01-10 2019-08-01 美商克拉治療有限責任公司 包含二羧酸之醫藥組合物及其治療應用
US11701334B2 (en) 2018-01-10 2023-07-18 Cura Therapeutics, Llc Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
KR102245539B1 (ko) * 2018-02-12 2021-04-29 주식회사 지앤피바이오사이언스 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물
EP3768841A4 (de) 2018-03-23 2021-12-08 Eidos Therapeutics, Inc. Verfahren zur behandlung von ttr-amyloidose unter verwendung von ag10
US20210106699A1 (en) * 2018-03-29 2021-04-15 Case Western Reserve University Stabilized nanobubbles and microbubbles for diagnostic and therapeutic application
US11634484B2 (en) 2018-04-24 2023-04-25 Neuracle Science Co., Ltd. Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of neuropathic pain
CN112638387A (zh) 2018-06-14 2021-04-09 纽罗克里生物科学有限公司 Vmat2抑制剂化合物、组合物和与其相关的方法
WO2020006341A1 (en) 2018-06-29 2020-01-02 Conatus Pharmaceuticals, Inc. (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
BR112021000934A2 (pt) 2018-07-20 2021-04-27 Pierre Fabre Medicament receptor para vista
EP3836926A4 (de) 2018-08-15 2022-05-04 Neurocrine Biosciences, Inc. Verfahren zur verabreichung bestimmter vmat2-inhibitoren
BR112020026493A2 (pt) 2018-08-17 2021-03-23 Eidos Therapeutics, Inc. Formulações de ag10
CN112969503A (zh) 2018-10-03 2021-06-15 斯塔滕生物技术有限公司 对人类和食蟹猕猴apoc3具有特异性的抗体和其使用方法
CA3119341A1 (en) 2018-11-16 2020-05-22 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
KR20200071198A (ko) 2018-12-10 2020-06-19 네오이뮨텍, 인코퍼레이티드 Nrf2 발현 조절 기반 T 세포 항암면역치료법
EP3898609A1 (de) 2018-12-19 2021-10-27 Shy Therapeutics LLC Mit der ras-superfamilie interagierende verbindungen zur behandlung von krebs, entzündlichen erkrankungen, rasopathien und fibrotischen erkrankungen
CN109602450B (zh) * 2019-01-29 2021-04-30 北京大学第三医院（北京大学第三临床医学院） 一种超声腔内探头隔离及导声一体化装置
US11447468B2 (en) 2019-02-06 2022-09-20 Dice Alpha, Inc. IL-17 ligands and uses thereof
MA55080A (fr) 2019-02-26 2022-01-05 Inspirna Inc Anticorps anti-mertk à affinité élevée et utilisations associées
WO2020181165A1 (en) 2019-03-07 2020-09-10 Conatus Pharmaceuticals Inc. Caspase inhibitors and methods of use thereof
CN114222803A (zh) 2019-05-20 2022-03-22 尼尔瓦纳科学股份有限公司 窄发射染料、包含其的组合物以及制备和使用其的方法
EP3996813A1 (de) 2019-07-11 2022-05-18 Cura Therapeutics, LLC Phenylverbindungen und pharmazeutische zusammensetzungen davon sowie deren therapeutische anwendungen
CA3146157A1 (en) 2019-07-11 2021-01-14 Cura Therapeutics, Llc Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
US11680098B2 (en) 2019-08-30 2023-06-20 Agenus Inc. Antibodies that specifically bind human CD96
WO2021055376A1 (en) 2019-09-16 2021-03-25 Dice Alpha, Inc. Il-17a modulators and uses thereof
CN114945409A (zh) 2020-01-13 2022-08-26 新免疫技术有限公司 用il-7蛋白和双特异性抗体的组合治疗肿瘤的方法
WO2021151001A1 (en) 2020-01-22 2021-07-29 Outpace Bio, Inc. Chimeric polypeptides
AU2021217373A1 (en) 2020-02-05 2022-08-04 Neoimmunetech, Inc. Method of treating a solid tumor with a combination of an IL-7 protein and CAR-bearing immune cells
WO2021242970A1 (en) 2020-05-29 2021-12-02 Boulder Bioscience Llc Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane
EP4168414A1 (de) 2020-06-18 2023-04-26 Shy Therapeutics LLC Substituierte thienopyrimidine zur interaktion mit der ras-superfamilie zur behandlung von krebs, entzündlichen erkrankungen, rasopathien und fibrotischen erkrankungen
CN111729093B (zh) * 2020-06-29 2022-05-24 南京超维景生物科技有限公司 一种造影剂成膜剂组合物、造影剂成膜脂液、造影剂及其制备方法
CN111617267A (zh) * 2020-07-07 2020-09-04 南京大学 一种包载全氟化碳的纳米级超声造影剂
WO2022061348A1 (en) 2020-09-16 2022-03-24 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2022087335A1 (en) 2020-10-23 2022-04-28 Biotheryx, Inc. Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
KR20230104176A (ko) 2020-11-02 2023-07-07 네오이뮨텍, 인코퍼레이티드 코로나바이러스의 치료를 위한 인터류킨-7의 용도
KR20230104175A (ko) 2020-11-05 2023-07-07 네오이뮨텍, 인코퍼레이티드 Il-7 단백질과 뉴클레오타이드 백신의 조합물을 사용한 종양의 치료 방법
JP2024500377A (ja) 2020-12-14 2024-01-09 バイオセリックス， インコーポレイテッド Ｐｄｅ４分解剤、医薬組成物、及び治療的応用
WO2022165000A1 (en) 2021-01-27 2022-08-04 Shy Therapeutics, Llc Methods for the treatment of fibrotic disease
EP4284377A1 (de) 2021-01-27 2023-12-06 Shy Therapeutics LLC Verfahren zur behandlung von fibrotischen erkrankungen
AU2022232625A1 (en) 2021-03-10 2023-09-28 Dice Molecules Sv, Inc. Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof
EP4326721A1 (de) 2021-04-22 2024-02-28 Protego Biopharma, Inc. Spirocyclische imidazolidinone und imidazolidindione zur behandlung von leichtkettiger amyloidose
EP4347568A1 (de) 2021-05-27 2024-04-10 Protego Biopharma, Inc. Heteroaryldiamid-ire1/xbp1s-aktivatoren
WO2022251644A1 (en) 2021-05-28 2022-12-01 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
EP4347826A1 (de) 2021-06-02 2024-04-10 Lyell Immunopharma, Inc. Nr4a3-defiziente immunzellen und verwendungen davon
IL309349A (en) 2021-06-14 2024-02-01 argenx BV Antibodies against interleukin 9 and methods of using them
WO2022266249A1 (en) 2021-06-16 2022-12-22 Biotheryx, Inc. Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
EP4355741A1 (de) 2021-06-16 2024-04-24 Biotheryx, Inc. Sos1-proteinabbauer, pharmazeutische zusammensetzungen daraus und ihre therapeutischen anwendungen
WO2023055045A1 (ko) 2021-09-29 2023-04-06 주식회사 엔바이오스 코일드 코일 융합 단백질
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
WO2023130081A1 (en) 2021-12-30 2023-07-06 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
WO2023129577A1 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
US20230348909A1 (en) 2022-03-30 2023-11-02 Biomarin Pharmaceutical Inc. Dystrophin exon skipping oligonucleotides
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
WO2023201282A1 (en) 2022-04-14 2023-10-19 Bristol-Myers Squibb Company Novel gspt1 compounds and methods of use of the novel compounds
US20230416741A1 (en) 2022-05-05 2023-12-28 Biomarin Pharmaceutical Inc. Method of treating duchenne muscular dystrophy
WO2023220640A1 (en) 2022-05-10 2023-11-16 Biotheryx, Inc. Cdk protein degraders, pharmaceutical compositions, and therapeutic applications
WO2023225665A1 (en) 2022-05-19 2023-11-23 Lyell Immunopharma, Inc. Polynucleotides targeting nr4a3 and uses thereof
WO2024054832A1 (en) 2022-09-09 2024-03-14 Innovo Therapeutics, Inc. CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS
WO2024073473A1 (en) 2022-09-30 2024-04-04 Boulder Bioscience Llc Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury

Family Cites Families (239)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3015128A (en) * 1960-08-18 1962-01-02 Southwest Res Inst Encapsulating apparatus
NL302030A (de) 1962-12-21 1900-01-01
US3291843A (en) * 1963-10-08 1966-12-13 Du Pont Fluorinated vinyl ethers and their preparation
BE661981A (de) * 1964-04-03
US3594326A (en) * 1964-12-03 1971-07-20 Ncr Co Method of making microscopic capsules
US3968203A (en) * 1965-10-01 1976-07-06 Jerome G. Spitzer Aerosol astringent composition
US3488714A (en) * 1966-09-19 1970-01-06 Dow Chemical Co Formed laminate structure and method of preparation
US3615972A (en) * 1967-04-28 1971-10-26 Dow Chemical Co Expansible thermoplastic polymer particles containing volatile fluid foaming agent and method of foaming the same
US3532500A (en) * 1967-07-25 1970-10-06 Eastman Kodak Co Light sensitive vesicular composition comprising an azido-s-triazine compound
US3557294A (en) * 1967-10-12 1971-01-19 Allied Chem Fluorinated ethers as inhalation convulsants
US3479811A (en) * 1967-11-29 1969-11-25 Dow Chemical Co Yarn and method of making the same
US3732172A (en) * 1968-02-28 1973-05-08 Ncr Co Process for making minute capsules and prefabricated system useful therein
US3650831A (en) * 1969-03-10 1972-03-21 Armour Dial Inc Method of cleaning surfaces
US4027007A (en) * 1970-12-09 1977-05-31 Colgate-Palmolive Company Antiperspirants formulated with borax
US3873564A (en) * 1971-03-03 1975-03-25 Synvar Ass 2-Imidazolinyl-3-oxide-1-oxypropionic acid
US4108806A (en) * 1971-12-06 1978-08-22 The Dow Chemical Company Thermoplastic expandable microsphere process and product
US4179546A (en) * 1972-08-28 1979-12-18 The Dow Chemical Company Method for expanding microspheres and expandable composition
US3960583A (en) * 1974-05-02 1976-06-01 Philadelphia Quartz Company Method of preparing modified hollow, largely spherical particles by spray drying
CH588887A5 (de) * 1974-07-19 1977-06-15 Battelle Memorial Institute
US3945956A (en) * 1975-06-23 1976-03-23 The Dow Chemical Company Polymerization of styrene acrylonitrile expandable microspheres
US4138383A (en) * 1975-11-24 1979-02-06 California Institute Of Technology Preparation of small bio-compatible microspheres
GB1523965A (en) * 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
US4162282A (en) * 1976-04-22 1979-07-24 Coulter Electronics, Inc. Method for producing uniform particles
GB1599881A (en) * 1977-02-02 1981-10-07 Millington A R Preparation for diagnostic radiology
CH621479A5 (de) * 1977-08-05 1981-02-13 Battelle Memorial Institute
CH624011A5 (de) * 1977-08-05 1981-07-15 Battelle Memorial Institute
US4192859A (en) * 1978-09-29 1980-03-11 E. R. Squibb & Sons, Inc. Contrast media containing liposomes as carriers
US4310506A (en) * 1979-02-22 1982-01-12 California Institute Of Technology Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species
US4276885A (en) * 1979-05-04 1981-07-07 Rasor Associates, Inc Ultrasonic image enhancement
US4265251A (en) * 1979-06-28 1981-05-05 Rasor Associates, Inc. Method of determining pressure within liquid containing vessel
US4310505A (en) * 1979-11-08 1982-01-12 California Institute Of Technology Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances
US4342826A (en) * 1980-02-04 1982-08-03 Collaborative Research, Inc. Immunoassay products and methods
US4421562A (en) * 1980-04-13 1983-12-20 Pq Corporation Manufacturing process for hollow microspheres
US4344929A (en) * 1980-04-25 1982-08-17 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4315514A (en) * 1980-05-08 1982-02-16 William Drewes Method and apparatus for selective cell destruction
US4331654A (en) * 1980-06-13 1982-05-25 Eli Lilly And Company Magnetically-localizable, biodegradable lipid microspheres
US4681119A (en) * 1980-11-17 1987-07-21 Schering Aktiengesellschaft Method of production and use of microbubble precursors
US4442843A (en) * 1980-11-17 1984-04-17 Schering, Ag Microbubble precursors and methods for their production and use
US4657756A (en) * 1980-11-17 1987-04-14 Schering Aktiengesellschaft Microbubble precursors and apparatus for their production and use
WO1982001642A1 (en) 1980-11-17 1982-05-27 Med Inc Ultra Microbubble precursors and methods for their production and use
US4427330A (en) * 1981-03-03 1984-01-24 Carter Charles P Automatic fence picket stock conveyor for fence picket pointing machine
US4420442A (en) * 1981-04-13 1983-12-13 Pq Corporation Manufacturing process for hollow microspheres
US4533254A (en) * 1981-04-17 1985-08-06 Biotechnology Development Corporation Apparatus for forming emulsions
EP0068961A3 (de) * 1981-06-26 1983-02-02 Thomson-Csf Vorrichtung zur lokalen Erwärmung von biologischen Gewebe
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4426330A (en) * 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4569836A (en) * 1981-08-27 1986-02-11 Gordon Robert T Cancer treatment by intracellular hyperthermia
WO1983001068A1 (en) * 1981-09-23 1983-03-31 Baker, Alfred, George Hollow, bilayered silicate microspheres
DE3141641A1 (de) 1981-10-16 1983-04-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Ultraschall-kontrastmittel und dessen herstellung
BR8107560A (pt) * 1981-11-19 1983-07-05 Luiz Romariz Duarte Estimulacao ultra-sonica da consolidacao de fraturas osseas
US4540629A (en) * 1982-04-08 1985-09-10 Pq Corporation Hollow microspheres with organosilicon-silicate walls
DE3225848A1 (de) * 1982-07-07 1984-01-19 Schering AG, 1000 Berlin und 4709 Bergkamen Kortikoidhaltige zubereitung zur topischen applikation
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
DE3374522D1 (de) * 1982-10-26 1987-12-23 University Of Aberdeen
US4603044A (en) * 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4731239A (en) * 1983-01-10 1988-03-15 Gordon Robert T Method for enhancing NMR imaging; and diagnostic use
US4718433A (en) 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
US4572203A (en) * 1983-01-27 1986-02-25 Feinstein Steven B Contact agents for ultrasonic imaging
US4775522A (en) * 1983-03-04 1988-10-04 Children's Hospital Research Foundation, A Division Of Children's Hospital Medical Center NMR compositions for indirectly detecting a dissolved gas in an animal
US4981692A (en) * 1983-03-24 1991-01-01 The Liposome Company, Inc. Therapeutic treatment by intramammary infusion
US5141738A (en) * 1983-04-15 1992-08-25 Schering Aktiengesellschaft Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof
US4485193A (en) 1983-05-10 1984-11-27 The Dow Chemical Company Expandable synthetic resinous thermoplastic particles, method for the preparation thereof and the application therefor
US4900540A (en) * 1983-06-20 1990-02-13 Trustees Of The University Of Massachusetts Lipisomes containing gas for ultrasound detection
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4615879A (en) * 1983-11-14 1986-10-07 Vanderbilt University Particulate NMR contrast agents for gastrointestinal application
FR2563725B1 (fr) * 1984-05-03 1988-07-15 Dory Jacques Appareil d'examen et de localisation de tumeurs par ultrasons muni d'un dispositif de traitement localise par hyperthermie
EP0158441B2 (de) * 1984-03-08 2001-04-04 Phares Pharmaceutical Research N.V. Liposombildende Zusammensetzung
GB8407557D0 (en) * 1984-03-23 1984-05-02 Hayward J A Polymeric lipsomes
US4728575A (en) * 1984-04-27 1988-03-01 Vestar, Inc. Contrast agents for NMR imaging
US5008109A (en) * 1984-05-25 1991-04-16 Vestar, Inc. Vesicle stabilization
US5008050A (en) * 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4620546A (en) * 1984-06-30 1986-11-04 Kabushiki Kaisha Toshiba Ultrasound hyperthermia apparatus
SE8403905D0 (sv) * 1984-07-30 1984-07-30 Draco Ab Liposomes and steroid esters
US4789501A (en) * 1984-11-19 1988-12-06 The Curators Of The University Of Missouri Glass microspheres
US4921706A (en) * 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
US4830858A (en) * 1985-02-11 1989-05-16 E. R. Squibb & Sons, Inc. Spray-drying method for preparing liposomes and products produced thereby
US4689986A (en) * 1985-03-13 1987-09-01 The University Of Michigan Variable frequency gas-bubble-manipulating apparatus and method
US5186922A (en) * 1985-03-15 1993-02-16 See/Shell Biotechnology, Inc. Use of biodegradable microspheres labeled with imaging energy constrast materials
US4663161A (en) * 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
JPS63500175A (ja) * 1985-05-22 1988-01-21 リポソ−ム　テクノロジ−，インコ−ポレイテツド リポソ−ム吸入法および吸入システム
DE3677112D1 (de) 1985-08-12 1991-02-28 Battelle Memorial Institute Poroese filtrierungsglaskugeln und methode zu deren herstellung.
US4684479A (en) * 1985-08-14 1987-08-04 Arrigo Joseph S D Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures
US4938947A (en) * 1985-11-01 1990-07-03 Centre National De La Recherche Scientifique (Cnrs) Aerosol composition for in vivo imaging
US4987154A (en) * 1986-01-14 1991-01-22 Alliance Pharmaceutical Corp. Biocompatible, stable and concentrated fluorocarbon emulsions for contrast enhancement and oxygen transport in internal animal use
US4927623A (en) * 1986-01-14 1990-05-22 Alliance Pharmaceutical Corp. Dissolution of gas in a fluorocarbon liquid
US4865836A (en) * 1986-01-14 1989-09-12 Fluoromed Pharmaceutical, Inc. Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport
EP0231091B1 (de) 1986-01-24 1993-03-31 Children's Hospital Medical Center Stabile Emulsionen von stark fluorierten, organischen Verbindungen
US4737323A (en) * 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4834964A (en) * 1986-03-07 1989-05-30 M.R.I., Inc. Use of charged nitroxides as NMR image enhancing agents for CSF
JPH0751496B2 (ja) * 1986-04-02 1995-06-05 武田薬品工業株式会社 リポソ−ムの製造法
DE3614657A1 (de) 1986-04-30 1987-11-05 Dornier Medizintechnik Pharmaka enthaltende lipidvesikel, verfahren zu ihrer herstellung und einbringung in den koerper eines lebewesens und freisetzung der in den lipidvesikeln enthaltende pharmaka
IL79559A0 (en) 1986-07-29 1986-10-31 Univ Ramot Contrast agents for nmr medical imaging
FR2602774B1 (fr) * 1986-07-29 1990-10-19 Atta Nouvelles molecules amphiphiles polyhydroxylees et perfluoroalkylees ayant des proprietes tensioactives
US4728578A (en) * 1986-08-13 1988-03-01 The Lubrizol Corporation Compositions containing basic metal salts and/or non-Newtonian colloidal disperse systems and vinyl aromatic containing polymers
US4776991A (en) * 1986-08-29 1988-10-11 The United States Of America As Represented By The Secretary Of The Navy Scaled-up production of liposome-encapsulated hemoglobin
JPS6360943A (ja) * 1986-09-01 1988-03-17 Green Cross Corp:The 超音波診断造影剤
US4781871A (en) * 1986-09-18 1988-11-01 Liposome Technology, Inc. High-concentration liposome processing method
US4769241A (en) * 1986-09-23 1988-09-06 Alpha Therapeutic Corporation Apparatus and process for oxygenation of liquid state dissolved oxygen-carrying formulation
ZW11287A1 (en) * 1986-11-04 1989-01-25 Aeci Ltd Process for the production of an explosive
DE3637926C1 (de) * 1986-11-05 1987-11-26 Schering Ag Ultraschall-Manometrieverfahren in einer Fluessigkeit mittels Mikroblaeschen
US5049388A (en) * 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US4863717A (en) * 1986-11-10 1989-09-05 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Methods for circumventing the problem of free radial reduction associated with the use of stable nitroxide free radicals as contrast agents for magnetic reasonance imaging
JPH0722311B2 (ja) * 1986-11-13 1995-03-08 キヤノン株式会社 カラ−画像読み取り装置
US4933121A (en) * 1986-12-10 1990-06-12 Ciba Corning Diagnostics Corp. Process for forming liposomes
DK175531B1 (da) 1986-12-15 2004-11-22 Nexstar Pharmaceuticals Inc Leveringsvehikel med amphiphil-associeret aktiv bestanddel
CA1321048C (en) * 1987-03-05 1993-08-10 Robert W. J. Lencki Microspheres and method of producing same
US5000960A (en) * 1987-03-13 1991-03-19 Micro-Pak, Inc. Protein coupling to lipid vesicles
US5219538A (en) * 1987-03-13 1993-06-15 Micro-Pak, Inc. Gas and oxygen carrying lipid vesicles
CH672733A5 (de) 1987-05-22 1989-12-29 Bracco Ind Chimica Spa
AU610910B2 (en) * 1987-06-23 1991-05-30 Hafslund Nycomed Innovation Ab Improvements in and relating to magnetic resonance imaging
US5354549A (en) 1987-07-24 1994-10-11 Nycomed Imaging As Iodinated esters
DE3741201A1 (de) 1987-12-02 1989-06-15 Schering Ag Ultraschallarbeitsverfahren und mittel zu dessen durchfuehrung
IE61591B1 (en) 1987-12-29 1994-11-16 Molecular Biosystems Inc Concentrated stabilized microbubble-type ultrasonic imaging agent and method of production
US4844882A (en) * 1987-12-29 1989-07-04 Molecular Biosystems, Inc. Concentrated stabilized microbubble-type ultrasonic imaging agent
US5425366A (en) * 1988-02-05 1995-06-20 Schering Aktiengesellschaft Ultrasonic contrast agents for color Doppler imaging
DE3803972A1 (de) 1988-02-05 1989-08-10 Schering Ag Ultraschallkontrastmittel
WO1989006978A1 (en) 1988-02-05 1989-08-10 Schering Aktiengesellschaft Berlin Und Bergkamen Ultrasonic contrast agents, process for producing them and their use as diagnostic and therapeutic agents
US4898734A (en) * 1988-02-29 1990-02-06 Massachusetts Institute Of Technology Polymer composite for controlled release or membrane formation
DE3812816A1 (de) 1988-04-16 1989-11-02 Lawaczeck Ruediger Dipl Phys P Verfahren zur solubilisierung von liposomen und/oder biologischer membranen sowie deren verwendung
US5171755A (en) * 1988-04-29 1992-12-15 Hemagen/Pfc Emulsions of highly fluorinated organic compounds
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
US4893624A (en) * 1988-06-21 1990-01-16 Massachusetts Institute Of Technology Diffuse focus ultrasound hyperthermia system
DE3824354A1 (de) 1988-07-19 1990-01-25 Basf Ag Verfahren zur herstellung von zellhaltigen kunststoffen nach dem polyisocyanat-polyadditionsverfahren mittels lagerstabiler, treibmittelhaltiger emulsionen und diese emulsionen
US4993415A (en) * 1988-08-19 1991-02-19 Alliance Pharmaceutical Corp. Magnetic resonance imaging with perfluorocarbon hydrides
US4996041A (en) * 1988-08-19 1991-02-26 Toshiyuki Arai Method for introducing oxygen-17 into tissue for imaging in a magnetic resonance imaging system
DE3828905A1 (de) 1988-08-23 1990-03-15 Schering Ag Mittel bestehend aus cavitate oder clathrate bildenden wirt/gast-komplexen als kontrastmittel
US5045304A (en) * 1988-08-31 1991-09-03 Wayne State University Contras agent having an imaging agent coupled to viable granulocytes for use in magnetic resonance imaging of abscess and a method of preparing and using same
US5410516A (en) * 1988-09-01 1995-04-25 Schering Aktiengesellschaft Ultrasonic processes and circuits for performing them
DE3829999A1 (de) 1988-09-01 1990-03-15 Schering Ag Ultraschallverfahren und schaltungen zu deren durchfuehrung
US4957656A (en) * 1988-09-14 1990-09-18 Molecular Biosystems, Inc. Continuous sonication method for preparing protein encapsulated microbubbles
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
FR2637182B1 (fr) * 1988-10-03 1992-11-06 Lvmh Rech Compositions a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un ecdysteroide, de preference l'ecdysterone, ou l'un de ses derives; et compositions cosmetiques, pharmaceutiques, notamment dermatologiques, de sericulture ou phytosanitaires l'incorporant
US5114703A (en) * 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
DE69002767T2 (de) 1989-06-22 1994-03-17 Atta Fluor- und phosphorhaltige amphiphilische moleküle mit oberflächenaktiven eigenschaften.
US5019370A (en) * 1989-07-10 1991-05-28 University Of Kentucky Research Foundation Biodegradable, low biological toxicity radiographic contrast medium and method of x-ray imaging
US5194266A (en) * 1989-08-08 1993-03-16 Liposome Technology, Inc. Amphotericin B/cholesterol sulfate composition and method
US5562608A (en) 1989-08-28 1996-10-08 Biopulmonics, Inc. Apparatus for pulmonary delivery of drugs with simultaneous liquid lavage and ventilation
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5620689A (en) 1989-10-20 1997-04-15 Sequus Pharmaceuuticals, Inc. Liposomes for treatment of B-cell and T-cell disorders
US5230882A (en) * 1989-12-22 1993-07-27 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5228446A (en) * 1989-12-22 1993-07-20 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5352435A (en) * 1989-12-22 1994-10-04 Unger Evan C Ionophore containing liposomes for ultrasound imaging
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5305757A (en) * 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5209720A (en) * 1989-12-22 1993-05-11 Unger Evan C Methods for providing localized therapeutic heat to biological tissues and fluids using gas filled liposomes
US5149319A (en) * 1990-09-11 1992-09-22 Unger Evan C Methods for providing localized therapeutic heat to biological tissues and fluids
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5088499A (en) * 1989-12-22 1992-02-18 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5123414A (en) * 1989-12-22 1992-06-23 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5334381A (en) * 1989-12-22 1994-08-02 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
DE4004430A1 (de) 1990-02-09 1991-08-14 Schering Ag Aus polyaldehyden aufgebaute kontrastmittel
US5556610A (en) 1992-01-24 1996-09-17 Bracco Research S.A. Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method
US5445813A (en) 1992-11-02 1995-08-29 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
US5578292A (en) 1991-11-20 1996-11-26 Bracco International B.V. Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
IN172208B (de) 1990-04-02 1993-05-01 Sint Sa
US5672585A (en) 1990-04-06 1997-09-30 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5358702A (en) 1990-04-10 1994-10-25 Unger Evan C Methoxylated gel particle contrast media for improved diagnostic imaging
US5078994A (en) * 1990-04-12 1992-01-07 Eastman Kodak Company Microgel drug delivery system
JPH03297475A (ja) 1990-04-16 1991-12-27 Ken Ishihara 共振音波により薬物の放出を制御する方法
US5288446A (en) * 1990-04-23 1994-02-22 Sumitomo Rubber Industries, Ltd. Production of rubber article
US5205287A (en) * 1990-04-26 1993-04-27 Hoechst Aktiengesellschaft Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents
US5190982A (en) * 1990-04-26 1993-03-02 Hoechst Aktiengesellschaft Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents
US5137928A (en) * 1990-04-26 1992-08-11 Hoechst Aktiengesellschaft Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents
AU636481B2 (en) 1990-05-18 1993-04-29 Bracco International B.V. Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
US5196348A (en) 1990-06-11 1993-03-23 Air Products And Chemicals, Inc. Perfluoro-crown ethers in fluorine magnetic resonance spectroscopy of biopsied tissue
US5315997A (en) 1990-06-19 1994-05-31 Molecular Biosystems, Inc. Method of magnetic resonance imaging using diamagnetic contrast
US5215680A (en) * 1990-07-10 1993-06-01 Cavitation-Control Technology, Inc. Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
IL95743A (en) 1990-09-19 1993-02-21 Univ Ramot Method of measuring blood flow
JP3247374B2 (ja) * 1990-10-05 2002-01-15 ブラッコ インターナショナル ベスローテン フェンノートシャップ 超音波エコグラフィーに適切な中空気体封入微小球の安定懸濁物の製造のための方法
US5487390A (en) 1990-10-05 1996-01-30 Massachusetts Institute Of Technology Gas-filled polymeric microbubbles for ultrasound imaging
CA2098849C (en) 1990-12-20 2007-07-10 Ralph R. Weichselbaum Control of gene expression by ionizing radiation
US5107842A (en) 1991-02-22 1992-04-28 Molecular Biosystems, Inc. Method of ultrasound imaging of the gastrointestinal tract
US5144703A (en) * 1991-03-04 1992-09-08 Maire Laura M Bathtub liner
EP0504881B2 (de) 1991-03-22 2000-11-08 Katsuro Tachibana Verstärker zur Ultraschalltherapie von Erkrankungen sowie diesen enthaltende flüssige Arzneimittelzusammensetzungen
GB9106673D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
GB9106686D0 (en) * 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
US5874062A (en) 1991-04-05 1999-02-23 Imarx Pharmaceutical Corp. Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5496535A (en) 1991-04-12 1996-03-05 Alliance Pharmaceutical Corp. Fluorocarbon contrast media for use with MRI and radiographic imaging
US5147631A (en) * 1991-04-30 1992-09-15 Du Pont Merck Pharmaceutical Company Porous inorganic ultrasound contrast agents
JP3319754B2 (ja) 1991-06-03 2002-09-03 ニユコメド・イメージング・アクシエセルカペト 造影剤におけるまたは造影剤に関する改良
EP0660714B1 (de) * 1991-06-18 2003-07-02 ImaRx Pharmaceutical Corp. Neue liposomale arzneimittelfreisetzungssysteme
GB9116610D0 (en) 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
MX9205298A (es) 1991-09-17 1993-05-01 Steven Carl Quay Medios gaseosos de contraste de ultrasonido y metodo para seleccionar gases para usarse como medios de contraste de ultrasonido
US5409688A (en) * 1991-09-17 1995-04-25 Sonus Pharmaceuticals, Inc. Gaseous ultrasound contrast media
HU218018B (hu) * 1991-09-17 2000-05-28 Sonus Pharmaceuticals Inc. Gázos ultrahang-kontrasztanyag és eljárás ultrahang kontrasztanyaghoz megfelelő gázok kiválasztására
US5362477A (en) 1991-10-25 1994-11-08 Mallinckrodt Medical, Inc. 19F magnetic resonance imaging agents which include a nitroxide moiety
US5196183A (en) * 1991-12-04 1993-03-23 Sterling Winthrop Inc. Contrast agents for ultrasound imaging
GB9200387D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
GB9200388D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
IL104084A (en) * 1992-01-24 1996-09-12 Bracco Int Bv Sustainable aqueous suspensions of pressure-resistant and gas-filled blisters, their preparation, and contrast agents containing them
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
JP3325300B2 (ja) 1992-02-28 2002-09-17 株式会社東芝 超音波治療装置
US5247935A (en) 1992-03-19 1993-09-28 General Electric Company Magnetic resonance guided focussed ultrasound surgery
US5858399A (en) 1992-04-09 1999-01-12 Northwestern University Acoustically reflective liposomes and methods to make and use the same
WO1993020802A1 (en) 1992-04-09 1993-10-28 Northwestern University Acoustically reflective liposomes and methods to make and use the same
US5339814A (en) 1992-04-14 1994-08-23 Lasker Sigmund E Process for visualizing tissue metabolism using oxygen-17
US5846516A (en) 1992-06-03 1998-12-08 Alliance Pharmaceutial Corp. Perfluoroalkylated amphiphilic phosphorus compounds: preparation and biomedical applications
DE4221256C2 (de) 1992-06-26 1997-07-10 Lancaster Group Ag Galenische Zusammensetzung für die topische Anwendung
US5552155A (en) 1992-12-04 1996-09-03 The Liposome Company, Inc. Fusogenic lipsomes and methods for making and using same
US5558855A (en) 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
WO1994016739A1 (en) 1993-01-25 1994-08-04 Sonus Pharmaceuticals, Inc. Phase shift colloids as ultrasound contrast agents
FR2700952B1 (fr) 1993-01-29 1995-03-17 Oreal Nouvelles compositions cosmétiques ou dermopharmaceutiques sous forme de gels aqueux modifiés par addition de microsphères expansées.
DK0693924T4 (da) 1993-02-22 2008-08-04 Abraxis Bioscience Inc Fremgangsmåde til (in vivo) levering af biologiske materialer og sammensætninger, der er egnede dertil
US5362478A (en) 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
AU6365894A (en) 1993-03-16 1994-10-11 Alliance Pharmaceutical Corporation Fluorocarbon compositions containing a visible or fluorescent label
US5567415A (en) 1993-05-12 1996-10-22 The Board Of Regents Of The University Of Nebraska Ultrasound contrast agents and methods for their manufacture and use
US5701899A (en) 1993-05-12 1997-12-30 The Board Of Regents Of The University Of Nebraska Perfluorobutane ultrasound contrast agent and methods for its manufacture and use
US5716597A (en) 1993-06-04 1998-02-10 Molecular Biosystems, Inc. Emulsions as contrast agents and method of use
BR9406993A (pt) 1993-07-02 1996-09-10 Molecular Biosystems Inc Microesferas de gases insolúveis encapsulados com proteína e sua preparação e uso como agentes de imagem ultrassônica
US5855865A (en) 1993-07-02 1999-01-05 Molecular Biosystems, Inc. Method for making encapsulated gas microspheres from heat denatured protein in the absence of oxygen gas
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
DK0711179T3 (da) 1993-07-30 2005-02-14 Imcor Pharmaceutical Co Stabiliserede sammensætninger med mikrobobler til ultralyd
US5433204A (en) * 1993-11-16 1995-07-18 Camilla Olson Method of assessing placentation
ZA952485B (en) 1994-03-28 1995-12-15 Nycomed Imaging As Liposomes
US5545396A (en) 1994-04-08 1996-08-13 The Research Foundation Of State University Of New York Magnetic resonance imaging using hyperpolarized noble gases
CA2189366A1 (en) 1994-05-03 1995-11-09 Kenneth J. Widder Composition for ultrasonically quantitating myocardial perfusion
US5571797A (en) 1994-05-11 1996-11-05 Arch Development Corporation Method of inducing gene expression by ionizing radiation
US5502094A (en) 1994-05-20 1996-03-26 Minnesota Mining And Manufacturing Company Physiologically acceptable emulsions containing perfluorocarbon ether hydrides and methods for use
US5736121A (en) 1994-05-23 1998-04-07 Imarx Pharmaceutical Corp. Stabilized homogenous suspensions as computed tomography contrast agents
US5562893A (en) 1994-08-02 1996-10-08 Molecular Biosystems, Inc. Gas-filled microspheres with fluorine-containing shells
US5509896A (en) 1994-09-09 1996-04-23 Coraje, Inc. Enhancement of thrombolysis with external ultrasound
US5540909A (en) 1994-09-28 1996-07-30 Alliance Pharmaceutical Corp. Harmonic ultrasound imaging with microbubbles
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
EP0727225A3 (de) 1995-02-14 1997-01-15 Sonus Pharma Inc Zusammensetzungen und Verfahren zur Herstellung von gerichteter Ultraschallabbildung
US5556372A (en) 1995-02-15 1996-09-17 Exogen, Inc. Apparatus for ultrasonic bone treatment
US5560364A (en) 1995-05-12 1996-10-01 The Board Of Regents Of The University Of Nebraska Suspended ultra-sound induced microbubble cavitation imaging
US5558092A (en) 1995-06-06 1996-09-24 Imarx Pharmaceutical Corp. Methods and apparatus for performing diagnostic and therapeutic ultrasound simultaneously
US5606973A (en) 1995-06-07 1997-03-04 Molecular Biosystems, Inc. Liquid core microdroplets for ultrasound imaging
US5897851A (en) 1995-06-07 1999-04-27 Sonus Pharmaceuticals, Inc. Nucleation and activation of a liquid-in-liquid emulsion for use in ultrasound imaging
US5804162A (en) 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US5648098A (en) 1995-10-17 1997-07-15 The Board Of Regents Of The University Of Nebraska Thrombolytic agents and methods of treatment for thrombosis
US5840023A (en) 1996-01-31 1998-11-24 Oraevsky; Alexander A. Optoacoustic imaging for medical diagnosis
US5976501A (en) 1996-06-07 1999-11-02 Molecular Biosystems, Inc. Use of pressure resistant protein microspheres encapsulating gases as ultrasonic imaging agents for vascular perfusion
US5849727A (en) 1996-06-28 1998-12-15 Board Of Regents Of The University Of Nebraska Compositions and methods for altering the biodistribution of biological agents
US5846517A (en) 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions

Also Published As

Publication number Publication date
EP0712293B1 (de) 2003-03-05
CA2164845C (en) 2008-04-29
EP0712293A1 (de) 1996-05-22
WO1994028780A2 (en) 1994-12-22
AU683900B2 (en) 1997-11-27
CN1125654C (zh) 2003-10-29
JP2007314559A (ja) 2007-12-06
DE122007000024I1 (de) 2007-10-04
EP0712293A4 (de) 1998-05-06
JPH08511526A (ja) 1996-12-03
NL300267I1 (nl) 2007-05-01
ES2193161T3 (es) 2003-11-01
CA2164845A1 (en) 1994-12-22
CN1125389A (zh) 1996-06-26
JP4916969B2 (ja) 2012-04-18
JP4274387B2 (ja) 2009-06-03
US5853752A (en) 1998-12-29
US6479034B1 (en) 2002-11-12
DK0712293T3 (da) 2003-06-30
US6071495A (en) 2000-06-06
NL300267I2 (nl) 2007-10-01
EP1252885A2 (de) 2002-10-30
WO1994028780A3 (en) 1995-02-02
LU91325I2 (fr) 2007-05-16
AU7043194A (en) 1995-01-03
US5585112A (en) 1996-12-17
DE69432219T2 (de) 2003-12-04
DE69432219D1 (de) 2003-04-10
PT712293E (pt) 2003-07-31
EP1252885A3 (de) 2003-04-16
ATE233574T1 (de) 2003-03-15

Similar Documents

Publication Publication Date Title
ATE233574T1 (de) Verfahren zur herstellung von gasgefüllten lipid- mikropartikeln und gasgefüllte lipid- mikropartikel
DE69431753T2 (de) Verfahren zur bereitung von liposomen mit gaseinschlüssen
DE69332310T2 (de) Verfahren zur herstellung von vorgefüllten, sterilen abgabevorrichtungen.
HU9300036D0 (en) Method for producing o-glycosylized alpha-interferons and pharmaceutical preparatives containing them
DK85786A (da) Biologisk aktive fragmenter af human antihaemofilisk faktor og fremgangsmaade til fremstilling deraf
ATA148892A (de) Zubereitung zur stetigen und kontrollierten abgabe von medikamentösen substanzen und verfahren zu deren herstellung
DE68910969T2 (de) Verfahren und vorrichtung zur herstellung von lipidbläschen.
DE69117546T2 (de) Vorrichtung und Verfahren zur Herstellung von kreisabschnittförmigen Nuten
DE59604897D1 (de) Verfahren und vorrichtung zur herstellung von (cyclo)aliphatische biuretgruppen enthaltenden polyisocyanaten
DE69521349T2 (de) Verfahren und vorrichtung zur herstellung von aufgussbeuteln
SE8800080D0 (sv) Lekemedelskomposition
ATE127114T1 (de) Verfahren zur herstellung von pyrazolkarbonsäure und derivaten.
DE69314021D1 (de) Verfahren mit hohem nutzeffekt zur herstellung von cyclohexanol und cyclohexanon
DE69116606T2 (de) Bacterin zur Behandlung von Necrophorum-Krankheiten und Verfahren zur Herstellung
DE69719930D1 (de) Verfahren zur Herstellung von medizinischen Pflastern zur perkutanen Verabreichung, und Vorrichtung dafür
DE69023141D1 (de) Verfahren und vorrichtung zur herstellung hochreinen stickstoffes.
DE69813550D1 (de) Vorrichtung und verfahren zur herstellung von radioaktiven arzneimitteln zur verabreichung
ATE175315T1 (de) Verfahren zur herstellung von mandelmilch und damit hergestellte produkte
ATE97590T1 (de) Verfahren und vorrichtung zur herstellung von lipidblaeschen.
DE3991360T1 (de) Verfahren zur herstellung von wasserloeslichem primycin und seinen komponenten sowie von diese enthaltenden pharmazeutischen praeparaten